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ABSTRACT

THE ROLE OF MEK1/2 AND MEK5 IN MELATONIN-MEDIATED ACTIONS ON
OSTEOBLASTS AND OSTEOCLASTS DIFFERENTIATION, BONE FORMATION, BONE
MICROARCHITECTURE, AND BONE BIOMECHANICS

By
Fahima Munmun
August 2021

Dissertation supervised by Dr. Paula A. Witt-Enderby
Melatonin, the main endogenous hormone to entrain the circadian system, is not limited to
its role in regulating the sleep-wake cycle; rather, it affects a wide variety of systems involving
antioxidant, anti-inflammation, blood pressure regulation, seasonal reproduction, ovarian
physiology, and immune function. Driven by the diversity of its action, melatonin for a long time
has also been studied in the field of bone and mineral research both clinically and pre-clinically.
Exogenous administration of melatonin in clinical trials in perimenopausal women (MOPS;
NCT01152580); or postmenopausal women with osteopenia (MelaOST; NCT01690000 and
MOTS; NCT01870115) confirmed improvement of bone mineral density (BMD) (MelaOST;
MOTS) and bone marker turnover status (MOPS, MOTS). Studies involving preclinical animal
models also revealed melatonin’s effect in improving age-related bone loss and BMD with efficacy
similar to a therapeutically relevant estrogen and progesterone hormone therapy. At the cellular
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level, this increase in BMD by melatonin was accompanied by increases in the levels of osteogenic
proteins, pErk1/2, and pErk5, indicating the potential role of the MAPKs, MEK1/2/ERK1/2 and
MEK5/ERK5 pathways in mediating melatonin’s action. To investigate this further, the goal of
this project was to study the role of MEK1/2 and MEK5 in regulating melatonin-mediated
osteoblast and osteoclast differentiation and function in vitro and in vivo and their role in
modulating bone density, quality, strength, and formation. In vitro, using small-molecule inhibitors
and a co-culture model of human bone marrow-derived mesenchymal stem cells (hMSCs) and
peripheral blood monocytes (hPBMCs), it was discovered that melatonin’s stimulating effect on
osteoblastogenesis is mediated through MT2 melatonin receptors, MEK1/2, MEK5, and perhaps
PPARγ and GLUT4. To further confirm the involvement of MEK1/2 and MEK5 in melatonin’s
effect, CRISPR/Cas9 knockout approaches were used to generate MEK1KO or MEK5KO hMSCs
and mouse mesenchymal stem cells (mMSCs). Both monoculture and co-culture models were
developed using these MEK1KO or MEK5KO MSCs with a goal to study the role of melatonin,
melatonin receptors, MEK1/2, and MEK5 in osteoblast and osteoclast differentiation and
communication between these cells. In both human and mouse MSCs, melatonin’s effect on
osteoblastogenesis was occurring strictly through MT2R-mediated actions on MEK5 and/or
MEK1 and not through an indirect action of melatonin on MEK5 or MEK1, consistent with the
findings using small molecule inhibitors. In vivo and using small molecule inhibitors or a
CRISPR/Cas9 knockout approach, it was further determined that Mek1/2 and 5 were primary
drivers underlying melatonin’s actions on bone formation, bone microarchitecture, and bone
biomechanics. In the small molecule inhibitor study where Balb(c) mice (female) were injected
with melatonin in the absence or presence of selective MEK1/2, MEK5, or MEK1/2/5 inhibitors
for 45 days, it was demonstrated that melatonin, through MEK1/2 and MEK5, increased
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osteogenic protein expression (Runx2, Bmp-2, Fra-1, Opg) and decreased metabolic protein, Pparγ
expression; and also modulated bone microarchitecture (i.e., trabecular number, separation, and
connectivity density) and bone mechanical properties (i.e., ultimate stress). A mouse calvarial
defect model was developed using PLGA scaffolds seeded with mMSCs (wildtype, control,
Mek1KO, Mek5KO) and placed into critical size calvarial defects created in Balb(c) mice (male
and female) followed by treatment with vehicle or melatonin nightly for 90 days. This study
demonstrated the involvement of Mek1 and Mek5 in new bone formation induced by melatonin in
both genders supporting the findings in vitro in human and mouse MSCs. Gender-specific analyses
of the calvarial data revealed unique gender differences in melatonin’s effect and kinase interaction
with melatonin. These mechanisms of action demonstrating a unique role for Mek1/2 and Mek5
in mediating both osteogenic and metabolic pathways as well as demonstrating specificity of action
in a gender-specific manner opens up new avenues of research examining conditions known to
promote bone loss (i.e., diabetes, aging) in males and females and novel therapeutic strategies and
agents to modulate bone loss to prevent fracture and mortality.
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Chapter 1: Introduction
1. 1. Bone
The human skeletal system is made up of bone or osseous tissue and cartilage. Osseous tissue is
divided into two structurally and functionally bone types—cortical bone (80% of bone volume)
and trabecular bone (20% of bone volume) (Amstrup, Sikjaer, Mosekilde, & Rejnmark, 2013;
Clarke, 2008). Although most bone within the body consists of both types of tissue, there are some
that have more cortical bone than trabecular bone (e.g., hip) or more trabecular bone than cortical
bone (e.g., vertebrae) (Amstrup et al., 2013; Clarke, 2008). Osseous tissue consists of different
cell types (i.e., osteoblasts, osteoclasts, osteocytes, and stem cells), minerals (i.e., calcium,
phosphate), and bone matrix (e.g., collagen) that gives bone both compressional and tensile
strength (Clarke, 2008). These cells control skeletal development, bone adaptation (modeling),
and bone preservation (remodeling) via their communication to maintain their activity and
evolution (Buck & Dumanian, 2012).
1.1.1. Dynamics of the bone remodeling process
A fine lifelong balance exists between osteoclast-mediated bone resorption and osteoblastmediated bone formation in response to physiological stimuli—for better (e.g., exercise, good diet)
or worse (e.g., aging, smoking, excessive alcohol consumption, high fat diet, menopause, circadian
misalignment, steroid anti-inflammatory medications) (Amstrup et al., 2013; Clarke, 2008; S. M.
A. Witt-Enderby, 2017). Bone remodeling is the normal physiological bone turnover process. The
osteoblast is the primary driver of the bone remodeling process, which aids in the formation of
new bone and also modulates the activity of osteoclasts through the release of receptor activator
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of nuclear factor kappa B ligand (RANKL), and osteoprotegerin (OPG), a RANKL decoy receptor
(Amstrup et al., 2013; Clarke, 2008).
Through active bone resorption, different signaling molecules (i.e., transforming growth factorbeta (TGF- β), insulin-like growth factor 1 (IGF-1) and 2 (IGF-2), bone morphogenetic proteins
(BMPs), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) are released
from the bone matrix (Clarke, 2008; Kearns, Khosla, & Kostenuik, 2008). These signaling
molecules drive the differentiation, recruitment, and activity of osteoclasts and osteoblasts in a
coordinated and balanced manner to form regular and high-quality bone (Clarke, 2008; Kearns et
al., 2008). Osteoblasts can also regulate osteoclastogenesis through the production and release of
macrophage colony-stimulating factor (M-CSF) and RANKL (a transmembrane protein), which
can be inhibited by osteoblast-mediated OPG release (Boyle, Simonet, & Lacey, 2003). RANKL,
after binding to receptor activator of nuclear factor kappa B (RANK) on the surface of osteoclast
precursors (mononuclear cells) stimulates recruitment of the adaptor protein, tumor necrosis factor
receptor-associated factor 6 (TRAF6), which then activates multiple signaling proteins to promote
the fusion of multiple mononuclear cells to form multinucleated osteoclasts (Atkins et al., 2006).
Besides RANKL and RANK, there are other downstream signaling proteins involved in osteoclast
differentiation, activity, and survival that include: nuclear factor kappa B (NFκB), protein kinase
B (Akt/PKB), mechanistic target of rapamycin (mTOR), the mitogen activated protein kinases
(MAPKs), c-Jun N-terminal kinases (JNK), extracellular signal-regulated kinases (ERK), and p38 (S. & A., 2014).
Through secretion of cathepsin K and tartrate-resistant acid phosphatase (TRAP) onto the
bone matrix, mature osteoclasts dissolve the bone matrix to get rid of old bone (Boyce, 2013;
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Boyce & Xing, 2007a; Boyle et al., 2003). OPG, also secreted by osteoblasts, can inhibit
osteoclastogenesis by binding with RANKL and therefore regulating available RANKL for RANK
(Boyce & Xing, 2007b). RANKL: OPG ratios are mostly inversely related (Boyce & Xing, 2007a)
and change with the state of differentiation of the osteoblast (Atkins et al., 2003). Their relative
ratio to one another is critical to keeping the bone remodeling process balanced to prevent the
excessive bone formation or bone resorption.
The physiological bone remodeling process regulates calcium balance, repairs microscopic cracks
sustained during normal activity, and heals fractures (C. M. Swanson et al., 2018). Aging,
endocrine dyscrasia (e.g., estrogen deficiency), or use of medications like steroidal antiinflammatory drugs can alter bone metabolism and contribute to osteoclast-mediated bone loss (C.
M. Swanson et al., 2018). Loss of both types of bone—cortical bone through subendosteal
resorption and trabecular bone through repeated perforations—contributes to fragile bones and
increase the risk of stress zones and fractures (Amstrup et al., 2013; Ensrud & Crandall, 2017).
1.1.2. Bone loss disorder: osteopenia and osteoporosis
Osteopenia can be defined as a disorder of the skeletal system characterized by a low bone mass
due to an irregularity in the bone remodeling system where the rate of bone resorption surpasses
the rate of bone formation resulting in weakened bone. According to the World Health
Organization’s diagnostic criteria, osteopenia is diagnosed in people when their T-score (scale of
bone mineral density, BMD) falls between -1.0 and -2.5 (inclusive) or is 1.0–2.5 standard
deviations below the mean of a healthy 30-year-old adult matched by sex and ethnicity. Untreated
osteopenia can eventually lead to osteoporosis (T-score <-2.5) and fragile bone susceptible to
future fractures. Other qualitative measures of bone included in this classification system are bone
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tissue deterioration and a disruption in one’s bone architecture (Cosman et al., 2014; "International
Osteoporosis Foundation,"). Both bone density and bone quality (i.e., shape and microarchitecture)
determine the bone’s ability to carry a mechanical load and resist fracture (Nih Consensus
Development Panel on Osteoporosis Prevention & Therapy, 2001).
Osteopenia and osteoporosis are considered a major growing public health challenge. Hip and
vertebral fractures are the most devastating consequences of osteopenia and osteoporosis as they
contribute to high morbidity and mortality (Ensrud & Crandall, 2017). Due to their close relation
with aging and lifestyle, an increase in the prevalence of osteopenia, osteoporosis, and fragility
fractures has been observed recently due to modern lifestyles (Reginster & Burlet, 2006). As a
matter of fact, by 2050, hip fracture is expected to increase by 310% in men and 240% in women
(Gullberg, Johnell, & Kanis, 1997; "International Osteoporosis Foundation," ; Oden, McCloskey,
Kanis, Harvey, & Johansson, 2015). An observational clinical study of 149,524 white
postmenopausal women (mean age 64.5 years.) revealed that after one year, 2259 women
experienced a new fracture, of which 82% were osteopenic (Siris et al., 2004), similar to what was
found from a 5.6-year study in postmenopausal women (Pasco et al., 2006). Current and future
statistics project that 1 in 3 women and 1 in 5 men, over age 50, will experience an osteoporosisrelated fracture in their lifetime worldwide (Curtis et al., 2016; "International Osteoporosis
Foundation," ; Kanis et al., 2000; Melton, Atkinson, O'Connor, O'Fallon, & Riggs, 1998; Melton,
Chrischilles, Cooper, Lane, & Riggs, 1992; Orwoll et al., 2005). Compared to other chronic noncommunicable diseases (i.e., rheumatoid arthritis, asthma, and hypertension), osteoporosis poses
a significant economic burden ("International Osteoporosis Foundation,"), which may be due, in
part, to the high mortality risk. For example, for a 50-year-old woman, her mortality risk due to
hip fracture is 2.8%, which is equivalent to her risk of death from breast cancer and four times
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higher risk of death from endometrial cancer ("International Osteoporosis Foundation,"). Although
fracture risk is higher in women, the mortality rate in men is approximately double that after the
first six months of fracture compared to that in similarly aged women ("International Osteoporosis
Foundation," ; Orwoll et al., 2005)—the reasons for which are unclear.
The US Preventive Services Task Forces and International Society for Clinical Densitometry
recommend that all women aged 65 years or older and men greater than 70 years (Lim, Hoeksema,
Sherin, & Committee, 2009; S. & A., 2014) have their BMD screened, especially in those who
are at higher risk for fracture due to risk factors such as low body weight, prior fracture, or highrisk medication (Lim et al., 2009). Moreover, bone quality/microarchitecture should also be tested
in conjunction with BMD measurements as bone microarchitectural changes (i.e., ↓ trabecular
number, thickness, connectivity density; ↑ trabecular space) has been associated with bone fragility
(Tranquilli Leali et al., 2009).
Even though the list of osteoporosis drugs is vast, variables associated with these conventional
osteoporotic therapies (e.g., stage of bone disease, adverse drug effects, co-morbidities) exist,
contributing to the issue of compliance resulting in a steady rise in fragility fracture-mediated
mortality rate (Amstrup, Sikjaer, Mosekilde, & Rejnmark, 2015; Kotlarczyk et al., 2012). The
aforementioned issues support the need to develop safe alternatives to prevent or treat bone loss.
Moreover, changes in modern lifestyle (e.g., high stress, poor diet, lack of exercise, sleep
disturbance) directs us towards interventions, other than drugs, which may improve health
outcomes (S. Maria et al., 2017; S. Maria & Witt-Enderby, 2014).
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1.1.3. Limitation of current bone loss therapies
Even though successful osteoporosis drugs are available, they are limited by their ability to
produce new bone, which is challenging in situations (i.e., severe osteoporosis) where new healthy
bone growth is required. Moreover, and as mentioned previously, due to their adverse effects, these
conventional osteoporosis therapies may contribute to a lack of patient compliance (Silverman &
Gold, 2010), ultimately contributing to the rise in mortality from fragility fracture (Amstrup,
Sikjaer, Mosekilde, et al., 2015; Kotlarczyk et al., 2012). Bisphosphonates have a high affinity for
calcium, which causes them to accumulate in the bone matrix through fluid endocytosis. This
property of bisphosphonates can become problematic, especially in bone that is highly perfused
(e.g., jaw) because its accumulation and subsequent osteoclast-inhibiting actions can lead to an
increased incidence of osteonecrosis of the jaw. Also, the bisphosphonates’ strong osteoclastinhibiting actions can produce an imbalance in bone remodeling (↓ resorption: ↑ deposition),
leading to irregular bone formation and subtrochanteric or femoral shaft fractures (Park-Wyllie et
al., 2011; Ruggiero, Mehrotra, Rosenberg, & Engroff, 2004; Rutkowski, 2011; Torres et al., 2008).
These side effects along with others (e.g., atrial fibrillation and esophageal cancer), are forcing
patients to go on a 3 to 5-year bisphosphonate drug holiday (McClung et al., 2013). A monoclonal
antibody generated against RANKL, denosumab, has been developed but its therapeutic use is
limited due to its adverse actions to potentially increase the risk of eczema and cellulitis
(Cummings et al., 2009), osteonecrosis of the jaw, and atypical femur fractures (Cosman et al.,
2014; Kyrgidis & Toulis, 2011). The selective estrogen receptor modulator, raloxifene, works
similar to estrogen in bone to inhibit osteoclasts but it may also increase the risk for deep venous
thrombosis and hot flashes (Grady et al., 2004). At present, there are two marketed bone anabolic
agents, teriparatide (Forteo/Forsteo) and abaloparatide (Tymlos). Teraparatide requires repeated
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daily injections and may increase the risk of developing osteosarcoma, thus limiting its use to 2
years (Vahle et al., 2002); two cases of osteosarcoma have been reported clinically in spite of its
short term use (Kawai, Modder, Khosla, & Rosen, 2011). Similar to teriparatide, abaloparatide,
also demonstrated an increased incidence in developing osteosarcoma in a rodent model (Jolette
et al., 2017).
Because of these various above mentioned reasons (e.g., stage of bone disease, adverse drug
effects, co-morbidities, preference), alternative approaches that include modification of diet and
lifestyle through yoga or meditation or by use of plant-derived estrogens (e.g., phytoestrogens)
(Kronenberg & Fugh-Berman, 2002), melatonin (Amstrup, Sikjaer, Mosekilde, et al., 2015;
Kotlarczyk et al., 2012), or herbal teas (Nash & Ward, 2017) are becoming popular among people
to manage their bone health. Along with their beneficial effects on bone, these alternative
approaches have a positive impact on the quality of life in both men and women (Lassila H, 2014;
S. Maria et al., 2018). Revealed by many health economic statistics, chronic bone diseases like
osteopenia and osteoporosis possess a high socio-economic burden and strongly impact on one’s
health and mortality providing the rationale and justification to develop new strategies to slow
and/or prevent bone loss (Burge et al., 2007; Lin & Lane, 2004).
1.2. Melatonin
1.2.1. Physiology and pharmacology
Aaron Lerner discovered melatonin in 1958 as a molecule playing a role in frog skin pigmentation
(Lerner, Case, Mori, & Wright, 1959), which was later established to be the main endogenous
hormone that modulates circadian rhythms (Claustrat, Brun, & Chazot, 2005; T. Li et al., 2019; F.
Yang et al., 2017) and the primary circadian output signal from the brain (Pevet & Challet, 2011).
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The synthesis of melatonin from the pineal gland is driven directly by the endogenous oscillator
located in the suprachiasmatic nucleus (SCN) or what is considered the master biological clock of
the hypothalamus. The melatonin synthesis pathway is regulated through a multi-synaptic neural
pathway that includes (in sequence) pre-autonomic neurons of the paraventricular nucleus of the
hypothalamus (PVN), sympathetic pre-ganglionic neurons of the intermediolateral cell column of
the spinal cord, and noradrenergic sympathetic neurons of the superior cervical ganglion (Larsen,
Enquist, & Card, 1998; Moore, 1996a, 1996b; Teclemariam-Mesbah, Ter Horst, Postema, Wortel,
& Buijs, 1999). Although the rhythm and secretion of melatonin are regulated by the SCN with a
periodicity close to 24h, the rhythm of melatonin secretion can be entrained to the light/dark cycle
if an intact retinohypothalamic tract (hypothalamus/paraventricular nuclei/pineal gland neuronal
connection) exists in the body. In this way, photic information from the retina, specifically retinal
ganglion cells with intrinsic photoreceptor capabilities, are sent to the SCN, which can entrain
these melatonin rhythms to be synchronized to the light/dark cycle resulting in higher melatonin
levels at night and lower levels during the day. When light, specifically blue light (~480nm), is
perceived by the retina, this results in the secretion of gamma-amino butyric acid (GABA) from
the SCN resulting in the inhibition of the neurons that synapse in the paraventricular nucleus
(PVN) of the hypothalamus. This interrupts the signal to the pineal gland and ultimately causes
inhibition of melatonin synthesis. On the other hand, the absence of light (or darkness) stimulates
the SCN to secrete glutamate, which stimulates the neuronal pathway to transmit signal from the
PVN. This information from the PVN is then conveyed in superior cervical ganglion (SCG) located
in the higher thoracic segments of spinal column to transmit the final signal to the pineal gland via
sympathetic postsynaptic fibers by releasing norepinephrine (NE). In the pinealocytes, NE triggers
the activation of enzyme arylalkylamine N-acetyltransferase (AA-NAT) gene transcription, which
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regulates melatonin biosynthesis (Aulinas, 2000; Cipolla-Neto & Amaral, 2018; Jagannath,
Taylor, Wakaf, Vasudevan, & Foster, 2017; Lockley, Arendt, & Skene, 2007; Reiter, Tan, &
Galano, 2014). Melatonin rhythms can also be regulated by other non-photic factors such as the
sympathetic nervous system (Stehle et al., 2011), sleep, exercise, odor, food/carbohydrate intake
and social interaction (Lockley et al., 2007).
Melatonin is mainly synthesized in the pinealocytes from the amino acid tryptophan where the
first step is the hydroxylation of tryptophan to 5-hydroxytryptophan followed by decarboxylation
yielding serotonin (Axelrod & Weissbach, 1960; Coon et al., 1995). Next, arylalkylamine- Nacetyltransferase (AA-NAT) acetylates serotonin to N-acetyl serotonin followed by methylation
by acetyl serotonin-O- methyltransferase (ASMT) to form melatonin (N-acetyl-5-methoxy
tryptamine) (Axelrod & Weissbach, 1960; Coon et al., 1995; Tordjman et al., 2017). As described
above, a multi-synaptic neural pathway modulates the pineal gland to control melatonin production
through a regulation of these enzymes— mainly AA-NAT and ASMT (Klein, 2004; Simonneaux
& Ribelayga, 2003). Melatonin can also be produced locally due to the presence of two critical
enzymes of the melatonin biosynthesis pathway, AA-NAT and ASMT, in many other tissues such
as the gastrointestinal tract, bone marrow, testes, and human lymphocytes (Conti et al., 2000;
Dubocovich & Markowska, 2005; Tan et al., 1999).
Amphiphilic in nature, pineal-derived melatonin easily reaches all tissues and can enter all
subcellular compartments.

Melatonin can bind to its membrane-bound G-protein coupled

receptors (MT1, MT2) located at the plasma or in mitochondrial membranes (Hill et al., 2015;
Lacoste et al., 2015; Maria S., 2014; Reiter et al., 2007; Suofu, Carlisle, Vilardaga, & Friedlander,
2018; Suofu et al., 2017), or to nuclear retinoid-related orphan nuclear (ROR/RZR) receptors,
(Becker-Andre et al., 1994; Lardone et al., 2011), or can work independently of receptors as a free
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radical scavenger (Acuna Castroviejo et al., 2002; Leon et al., 2004; Reiter, Acuna-Castroviejo,
Tan, & Burkhardt, 2001; Reiter, Calvo, Karbownik, Qi, & Tan, 2000; Reiter et al., 2014). Similar
to melatonin, melatonin receptors are also widely distributed within the central nervous system
(Reiter et al., 2001; Suofu et al., 2018) and in peripheral tissues (Slominski, Reiter, SchlabritzLoutsevitch, Ostrom, & Slominski, 2012), including bone (Radio, Doctor, & Witt-Enderby, 2006;
S. & A., 2014). Through these receptor-dependent or -independent pathways, melatonin affects
systems involving circadian entrainment, blood pressure regulation, seasonal reproduction,
ovarian physiology, oxidative stress/inflammation and immune function (Dominguez-Rodriguez,
Abreu-Gonzalez, Sanchez-Sanchez, Kaski, & Reiter, 2010).
MT1 melatonin receptor (MT1R)-dependent actions include modulation of neuronal firing, arterial
vasoconstriction, cancer cell proliferation, and modulation of reproductive and metabolic function.
In the central nervous system, melatonin, through MT2 melatonin receptors (MT2Rs), shifts
circadian rhythms of neuronal firing in the SCN and inhibits dopamine release in the retina. In
peripheral organs, MT2R-mediated actions include induction of vasodilation, inhibition of
leukocyte rolling in arterial beds, regulation of osteoblastogenesis through MAPK/Wnt-beta
catenin pathways, and enhancement of immune responses (Dubocovich & Markowska, 2005;
Maria S., 2014). Melatonin’s immunomodulatory and anti-inflammatory actions occur through its
interactions with nuclear (ROR/RZR) binding sites (Garcia-Maurino, Gonzalez-Haba, Calvo,
Goberna, & Guerrero, 1998; Hardeland, 2013; Reiter et al., 2014; Steinhilber et al., 1995) and free
radical scavenging properties/induction of oxidative stress, respectively (Reiter et al., 2001; Reiter,
Calvo, et al., 2000; Reiter et al., 2014; Reiter et al., 2007; Reiter, Tan, Osuna, & Gitto, 2000). Due
to its versatility of action at the cellular, tissue, and whole organism level melatonin can be
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considered to be a multifunctional homeostatic factor (Luchetti et al., 2010; H. M. Zhang & Zhang,
2014).
1. 2.2. Role of melatonin in bone remodeling
The circadian system, melatonin, and markers of bone health are closely related with a 24-hr
rhythm of nightly peaks and daytime troughs displayed by osteoblastic genes (also induced by
melatonin) (K. H. Park et al., 2011; Roth, Kim, Lin, & Cho, 1999; Sethi et al., 2010; L. Zhang et
al., 2010) and bone cells (mainly osteocytes) (Greenspan, Dresner-Pollak, Parker, London, &
Ferguson, 1997; Hassager, Risteli, Risteli, Jensen, & Christiansen, 1992; Heshmati et al., 1998;
Ostrowska, Kos-Kudla, Marek, & Kajdaniuk, 2003). Increases in the biochemical markers of bone
resorption [i.e., amino-terminal cross-linking telopeptide of type I collagen (NTX), C-terminal
telopeptide of type 1 collagen (CTX)] and, to a lesser degree, bone formation (osteocalcin, P1NP)
are observed during the hour of darkness, when melatonin levels are highest. Dysregulated bone
remodeling has been demonstrated in people with circadian disturbances such as children with
Smith–Magenis syndrome (Novakova, Nevsimalova, Prihodova, Sladek, & Sumova, 2012;
Potocki et al., 2000), shift workers (Feskanich, Hankinson, & Schernhammer, 2009; B. K. Kim,
Choi, & Chung, 2013) and women who are transitioning through or post menopause (Ostrowska,
Kos-Kudla, Marek, Swietochowska, & Gorski, 2001). These studies demonstrate that strong
associations between the light/dark cycle and melatonin rhythms exist (Qvist, Christgau, Pedersen,
Schlemmer, & Christiansen, 2002; C. Swanson et al., 2017; C. M. Swanson et al., 2018). Actually,
to ensure healthy, dense, and high-quality bone formation and maintenance, melatonin serves to
synchronize the circadian clocks in bone with the light/dark cycle and, in humans, with the
sleep/wake cycle (Greenspan et al., 1997; Hassager et al., 1992; Heshmati et al., 1998; Maria S.,
2014; Ostrowska, Kos-Kudla, Marek, et al., 2003; S. M. A. Witt-Enderby, 2017). Consequently,
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a disruption in one’s circadian rhythm could lead to adverse effects on bone physiology. In fact, it
was demonstrated from the Nurse’s Cohort Study in 38062 nurses that chronic shift work (greater
than 20 years) increased the risk of hip and wrist fracture (Feskanich et al., 2009). In a study
assessing BMD in 3005 people from Korea, low BMD resulted from shift work other than a work
schedule between 9-5 pm (B. K. Kim et al., 2013). Furthermore, in a study of 70 postmenopausal
nurses in Chile, it was demonstrated that shift work decreased BMD and increased the risk for
osteoporosis (Quevedo & Zuniga, 2010). These effects of circadian disruption observed in bone
are most likely attributable to the lowering of nocturnal melatonin levels due to light exposure at
night (LAN) (Graham, Cook, Gerkovich, & Sastre, 2001). Loss of nocturnal melatonin may
directly affect actions on osteoblasts and osteoclasts to lower or raise their activity, respectively,
or indirectly through melatonin’s actions on clock proteins and/or cortisol levels (Rahman, Wright,
Lockley, Czeisler, & Gronfier, 2019). In osteoblasts, clock gene expression, like Per2, can be
impacted by loss of nocturnal melatonin leading to altered osteoblastic gene expression and
proliferation as well as disrupted glucocorticoid rhythms (Bedrosian, Fonken, & Nelson, 2016; S.
M. A. Witt-Enderby, 2017). For glucocorticoids, this occurs because melatonin can modulate
cortisol levels (Ogle & Kitay, 1978), specifically during the early phase of darkness (Rahman et
al., 2019; Richter et al., 2008; Sewerynek & Lewinski, 1989).
Melatonin levels decrease with age and after menopause (Boskey & Coleman, 2010; Lassila H,
2014; Sack, Lewy, Erb, Vollmer, & Singer, 1986; Shen, Chyu, & Wang, 2013; P. A. Witt-Enderby,
Radio, Doctor, & Davis, 2006). These age-related declines in melatonin levels are also associated
with declines in the bone-protective steroid hormones: estrogen, progesterone, and testosterone.
The opposite occurs with cortisol where the age-related increases in cortisol are associated with
the breakdown of bone (Al-Azzawi & Palacios, 2009; Iguichi, Kato, & Ibayashi, 1982; Yiallouris
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et al., 2019). Imbalanced bone remodeling due to the loss and gain of bone-protective and
osteolytic hormones, respectively, may lead to progressive bone loss over time (Boskey &
Coleman, 2010), ultimately contributing to development of osteoporosis and fractures in the
elderly and the beginning of osteopenia, osteoporosis and fracture in peri- and postmenopausal
women (Greendale et al., 2020; Ladizesky et al., 2001; Uslu et al., 2007). In fact, 30% of all
postmenopausal women will develop osteoporosis and 40% will have one or more related fractures
during their lifetime (Reginster & Burlet, 2006). To preserve bone quality and density and prevent
future fracture, appropriately timed intervention strategies targeted to the menopausal transition,
especially during perimenopause when bone loss is rapid, should be given. Melatonin should be
considered as one of these interventional strategies because studies have demonstrated
improvement in bone markers in perimenopausal (3mg melatonin nightly for 6 months; MOPS;
NCT01152580) (Kotlarczyk et al., 2012); improvement in BMD in postmenopausal women with
osteopenia using 1or 3mg melatonin nightly for one year (MelaOST; NCT01690000) (Amstrup,
Sikjaer, Heickendorff, Mosekilde, & Rejnmark, 2015); and improvement in both P1NP and BMD
in postmenopausal women with osteopenia given melatonin 5mg with micronutrients nightly for
one year (MOTS: NCT01870115) (S. Maria et al., 2017).
Increases in oxidative stress and loss of defense (antioxidant) mechanisms through aging (Espino,
Pariente, & Rodriguez, 2012; Hotchkiss & Nelson, 2002; Reiter, Calvo, et al., 2000; Reiter, Tan,
et al., 2000) or estrogen deficiency may contribute to bone loss through an activation of osteoclast
activity. This may occur through RANKL-mediated increases in bone resorption and bone loss as
demonstrated (Altindag, Erel, Soran, Celik, & Selek, 2008; Amstrup et al., 2013; Baek et al., 2010;
Sheweita & Khoshhal, 2007). Melatonin possesses strong antioxidant enzyme induction properties
and free radical scavenging properties (Crespo et al., 1999; Gilad et al., 1998; Inal, Kanbak, &

13

Sunal, 2001; Leon, Acuna-Castroviejo, Escames, Tan, & Reiter, 2005; Poeggeler, Reiter, Tan,
Chen, & Manchester, 1993; Reiter et al., 2001; Reiter, Calvo, et al., 2000; Reiter et al., 2016; Reiter
et al., 2014; Reiter et al., 2007; Reiter, Tan, et al., 2000; Winiarska, Fraczyk, Malinska, Drozak,
& Bryla, 2006), which makes it an ideal molecule to maintain and promote bone health. Therefore,
a loss in the body’s inherent and efficacious antioxidants like melatonin and estrogen through
aging, hormone loss (menopause), and/or lifestyle (chronic jet lag, social jet lag, shift work)
(Bellanti et al., 2013; Reiter et al., 2016) may be inducing chronic inflammatory states in the body
resulting in the activation of inflammatory markers like NFκB and by increasing the production of
reactive oxygen species (ROS)(Grivennikov & Karin, 2010; Ruan & Chen, 2012).
High levels of ROS has inhibitory effects on osteoblastogenesis and stimulatory effects on
osteoclastogenesis gradually leading to low bone density, osteopenia, osteoporosis, and/or
osteoporosis-related fracture (Baek et al., 2010; Bai et al., 2004; N. K. Lee et al., 2005; Maria S.,
2014; Mody, Parhami, Sarafian, & Demer, 2001). So, chronic inflammation as seen in conditions
like rheumatoid arthritis or periodontitis and

oxidative stress are emerging as significant

contributing factors to the etiopathogenesis of RANKL-mediated bone loss and osteoporosis
(Arron & Choi, 2000; Lorenzo, 2000). Melatonin, through a dampening of these systems and
subsequent softening of RANKL levels, may reestablish or maintain a healthy balance between
RANKL and OPG ratios as supported by many but not all studies summarized in Table 1.
Table 1: Role of melatonin in bone remodeling: Clinical findings
HUMAN MODEL STUDIES
Endogenous/ Indirect Melatonin Effect
References
In post-menopausal women with bone deterioration, a negative (Ostrowska et
correlation exists between:
2001)
1) values of acrophase Mel and PICP rhythms
2) ICTP rhythms and both amplitude and acrophase of Mel
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al.,

Association between nightshift work and increased risk of wrist and hip
fractures was observed in postmenopausal nurses.
Irregular and regular (other than daytime) shift work is associated with
lower BMD, lower levels of serum 25-hydroxyvitamin D and higher
risk of osteopenia in other than daytime workers
Serum melatonin level is lower compared to normal in patient with AIS

(Feskanich et al.,
2009)
(B. K. Kim et al., 2013)

(Sadat-Ali, al-Habdan,
& al-Othman, 2000)
AIS patients have lower MT2 protein and mRNA expression compared (Yim et al., 2013)
to normal
Exogenous/ Direct Melatonin Effect (alone)
Exogenous melatonin administration in perimenopausal women for 6 (Kotlarczyk et al.,
months renormalizes imbalanced bone marker turnover (NTX:OC), 2012)
improves postmenopausal physical symptoms in MENQOL
Exogenous melatonin administration for 6 months improves mood and (S. Maria et al., 2018)
interrupted sleep cycle in perimenopausal women
Exogenous melatonin administration in postmenopausal women for 12 (Amstrup,
Sikjaer,
months increases BMD and is associated with decrease in urine calcium Heickendorff, et al.,
2015)
Exogenous melatonin administration for 12 months improves sleep (Amstrup,
Sikjaer,
quality in subgroup of postmenopausal women with sleep disturbance Mosekilde, et al.,
2015)
Exogenous Melatonin Effect (combined with strontium (citrate), vitamin D3 and vitamin K2
(MK7; MSDK)
MSDK administration in postmenopausal osteopenic women
(S. Maria et al., 2017)
increases BMD and
serum P1NP, decreased bone turnover
(CTx:P1NP), and improved mood and sleep quality. Mechanistically,
these changes were accompanied by ↑ osteoblast differentiation and
marker expression, ↓ osteoclast differentiation & markers (RANKL), ↓
metabolic proteins (PPARγ, GLUT4) expression.
Mel- Melatonin, PICP- Procollagen I carboxyterminal propeptide, ICTP- Carboxyterminal
telopeptide of type I collagen, BMD-Bone mineral density, AIS- Adolescents with idiopathic
scoliosis, QoL- Quality of Life, NTX- N-terminal telopeptide, OC/OCN-Osteocalcin, CTX- Nterminal telopeptide, P1NP- Procollagen type 1 N-terminal propeptide, RANKL- receptor
activator of nuclear factor kappa B ligand, PPARγ- Peroxisome proliferator-activated receptor
gamma, GLUT4- Glucose transporter type 4.
Findings from all the clinical studies conducted to date, support use for melatonin as another
alternative therapy for improving bone health through its reestablishment of circadian rhythms and
its positive actions on osteoblasts, inhibitory actions on osteoclasts and improvement in BMD.
Melatonin’s specific actions on osteoblasts and osteoclasts will be described in greater detail in
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chapters 3, 4 and 5 (Kotlarczyk et al., 2012; Sanchez-Barcelo, Mediavilla, Tan, & Reiter, 2010; P.
A. Witt-Enderby et al., 2006; Witt‐Enderby P, 2011).
1.2.3. Research objectives
The use of therapeutics, which are intended for the treatment of osteoporosis, should also maintain,
or improve the quality of life. Except for melatonin, there are no effective treatments that
simultaneously reverse the pathogenesis of osteoporosis as well as improve quality of life
(Kotlarczyk et al., 2012; S. Maria et al., 2018; S. Maria et al., 2017). Moreover, many of the
current osteoporosis therapies are fraught with side effects (Lassila H, 2014). Melatonin’s unique
pharmacology (i.e., receptor-dependent and -independent actions (S. Maria & Witt-Enderby, 2014)
and multidimensional actions in the body (i.e., circadian entrainment; osteoblast inducer,
osteoclast inhibitor, antioxidant/free radical scavenger) (S. Maria & Witt-Enderby, 2014; Sifat
Maria & Witt-Enderby, 2017) makes it an attractive candidate for maintaining healthy bone
through the aging process and through life in general. Along with its mechanistic versatility,
melatonin has demonstrated clinical efficacy and safety (Amstrup, Sikjaer, Heickendorff, et al.,
2015; Kotlarczyk et al., 2012; S. Maria et al., 2017). Drug targets should be expanded beyond that
of the osteoblast and osteoclast to improve (at least not deteriorate) quality of life by lowering
oxidative stress, inflammation, and realigning one’s circadian rhythms to coincide with the
light/dark cycle, sleep/wake cycle and melatonin rhythms. Moreover, to prevent, slow, or reverse
bone loss, strategies targeted to modify endogenous melatonin levels through natural means (e.g.,
minimizing light exposure at night, maximizing light exposure during the day) or by
supplementing declining nocturnal melatonin back to normal (replacement therapy) or to surpass
nocturnal melatonin peaks (therapeutic strategy) can be used to maintain, prevent, and reverse,
respectively, bone health.
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The long-term goal of the research conducted in the Witt-Enderby laboratory is to develop
melatonin as a novel therapy to simultaneously reverse the pathogenesis of osteoporosis as well as
improve quality of life. To pursue that goal, the objective of this study was to clarify the
mechanism(s) underlying melatonin’s actions on osteoblasts, osteoclasts, and bone (density and
quality) by studying kinases (MEK1/2/5) known to be involved in melatonin-mediated
osteoblastogenesis as demonstrated in vitro in human mesenchymal stem cells (hMSCs).
1.3. Overview of MEK1/2-ERK1/2 and MEK5-ERK5 Pathway:
1.3.1. MAPK signaling pathways
Among the numerous intracellular signaling pathways, the mitogen activated protein kinase
(MAPK) pathways play a more important role in cell proliferation, differentiation, apoptosis,
angiogenesis, and tumor metastasis than any other pathways. The ERK, JNK/stress-activated
protein kinase, p38 MAPK and ERK5 signal transduction pathways are the four MAPK cascades
that have been identified in eukaryotic cells. Each MAPK signaling cascade consists of at least
three tiers: MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and MAPK, which
activate each other successively and then eventually phosphorylate downstream proteins critical
in cellular proliferation, differentiation, and apoptosis (Plotnikov, Zehorai, Procaccia, & Seger,
2011; Wortzel & Seger, 2011). The JNK and p38 MAPK pathways are found mainly to be related
to stress and apoptosis of cells, whereas the most thoroughly studied MAPK signaling pathway,
the ERK/MAPK signaling pathway, is closely related to cell proliferation and differentiation; and
plays a pivotal role in the cell signal transduction network (Chang & Karin, 2001; Khokhlatchev
et al., 1998; Kolch, 2005; Kyriakis & Avruch, 2001).
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1.3.2 MEK1/2-ERK1/2 pathway
Well known for its prominent role in controlling gene expression (Nabet et al., 2015; S. H. Yang,
Sharrocks, & Whitmarsh, 2013), the MEK1/2-ERK1/2 signaling pathway is activated by a range
of extracellular stimuli. Common stimuli include growth and differentiation factors, hormones,
neuropeptides, and cytokines, acting through their cognate receptors (receptor tyrosine kinases, Gprotein coupled receptors, cytokine receptors, etc.). Encoded by distinct genes, all studied
mammalian cells express two canonical ERK proteins, ERK1 and ERK2, which contain 84%
identical amino acids and so they are highly homologous. Human ERK1 is larger than ERK2 by a
17 amino acid N-terminal extension and 2 extra amino acids at the C-terminus extension. The
MEK1/2-ERK1/2 signaling pathway consists of a three-tier hierarchical protein kinase cascade
including ERK1/2 (MAPKs), which are activated by MAPK Kinases (MEKs) which are, in turn,
activated by MAPKKKs (Cargnello & Roux, 2011).
Growth factors through binding to their receptors result in the activation of the RAS proteins by
recruiting guanine nucleotide exchange factors such as Son-of-Sevenless (SOS) to the plasma
membrane where they promote the dissociation and exchange of GDP for GTP from RAS proteins
switching RAS into its active conformation. The binding of RAS-GTP to RAF proteins forms
active homo- or heterodimers at the plasma membrane eventually leading to the phosphorylation
of MEK1/2, which then activates ERK1/2. Several different MAPKKKs, including the three RAF
protein kinases (ARAF, BRAF and CRAF), trigger autoactivation/phosphorylation of MEK1/2 at
conserved serine residues; this finding also results in the classification of MAPKs as
serine/threonine kinases. ERK1 and 2 are synthesized in cells as inactive zymogens, which become
active via phosphorylation of critical threonine and tyrosine residues in the T-E-Y motif found in
the kinase activation loop to allow the correct alignment of ATP and substrate for catalysis. The
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dual-specificity protein kinases, MEK1 or MEK2 (the MAPKKs), catalyze the ERK1/2 T-E-Y
motif by first phosphorylating the tyrosine and then the threonine in a progressive manner (Aoki,
Yamada, Kunida, Yasuda, & Matsuda, 2011). This unique RAF-MEK1/2-ERK1/2 cascade not
only brings these kinases in close proximity, but also serves other purposes that include forming
scaffolds that modulate distinct signaling cascades to turn them off (i.e., desensitize) or activating
and insulating the pathway from cross talk by other kinases (Good, Zalatan, & Lim, 2011).
Following MEK1/2-catalyzed phosphorylation, a significant fraction of ERK1/2 enters the nucleus
and directly binds to and phosphorylates transcriptional regulators controlling gene transcription
(Lidke et al., 2010). ERK1/2-mediated phosphorylation of a variety of sequence-specific
transcription factors (i.e., many members of ETS and AP-1 families) occurs modulating their
expression (O'Donnell, Odrowaz, & Sharrocks, 2012). Moreover, through ERK1/2-mediated
actions on cytosolic proteins, they can also control metabolism, mitochondrial fission, and cell
survival (Balmanno & Cook, 2009; Cook, Stuart, Gilley, & Sale, 2017). Due to its versatility of
action regulating cell fate, ERK1/2 signaling constitutes a major pathway for many growth factors,
cytokines, and hormones eventually regulating cell metabolism and function and influencing the
specific biological effects of cells (Schulze, Lehmann, Jefferies, McMahon, & Downward, 2001).
1.3.3. MEK5 pathway
The MEK5/ERK5 pathway, activated in response to growth factors and stress stimulation, has
been established as a distinctive MAPK signaling pathway (Flaherty et al., 2010). ERK5, the last
MAP kinase member discovered, is activated by the upstream kinase MEK5, which is activated
by its upstream modulators, MEKK2 or MEKK3, but not MEKK1 (Chang & Karin, 2001).
Although both MEKK2 and MEKK3 activate MEK5, MEK2 has a higher binding affinity for
MEK5 than MEKK3 (Sun et al., 2001). Although the kinase domains of MEKK3 and MEKK1 are
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very similar, their regulatory domains, located in the N-terminus, are very different rendering
MEKK3 but not MEKK1 capable of activating MEK5. MEKK proteins bind on the N-terminal
extension of MEK5 to modulate its activity (English, Vanderbilt, Xu, Marcus, & Cobb, 1995).

Two MEK5 isoforms, MEK5a and MEK5b, have been identified based on N-terminus splice
variants (English et al., 1995; Pearson, English, White, & Cobb, 2001). Between these two
isoforms, MEK5a is found to have higher affinity and is a stronger activator of ERK5 compared
to MEK5b. MEK5a has a novel MAPK docking site in the N-terminal domain, which is not
identical to other MEKs (X. Wang & Tournier, 2006). The binding of MEKK2/3 to MEK5 is
regulated by the N-terminal region of MEK5a, which includes a phox and Bem1p domain
(Nakamura & Johnson, 2003; Seyfried, Wang, Kharebava, & Tournier, 2005). The N-terminal
domain of MEK5 has also been proposed to contain an autoinhibitory domain that can regulate the
interaction of MEK5 with other kinases (Seyfried et al., 2005). The binding of MEKK2 with
MEK5 causes a conformational change in MEK5a exposing its Ser311 and Thr315 for
phosphorylation (Y. Wang et al., 2007). Interestingly, both MEKKs and ERK5 can bind to the Nterminal domain of MEK5a modulating its activity. Specifically, dissociation of MEKK from the
MEK5 complex is hypothesized as the way to allow MEK5 to interact with its ERK5 substrate
(Xia, Wu, Su, Murray, & Karin, 1998).

ERK5 is unique compared to the other MAPKs in its family with respect to size. The full-length
(2445 base pair) sequence of human ERK5 encodes for an 816 amino acid protein making ERK5
more than twice the size of other MAPKs. This size difference is primarily due to a 396 amino
acid C-terminus extension located on ERK5 giving it another name (i.e., big MAP kinase 1 or
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Bmk1). ERK5 shares 50% homology with ERK1/2 mostly through a highly conserved MAPK Nterminal catalytic domain (Mody, Leitch, Armstrong, Dixon, & Cohen, 2001; Moriguchi et al.,
1999). The C-terminal tail of ERK5 is thought to have an autoinhibitory function supported
through deletion studies demonstrating enhanced ERK5 activity following deletion of the Cterminal domains (Buschbeck & Ullrich, 2005; G. Zhou, Bao, & Dixon, 1995).

As stated previously, diverse stimuli can activate the MEK5/ERK5 pathway and it is the type of
stimuli and cell type that determines which signaling pathway will be activated (Chao, Hayashi,
Tapping, Kato, & Lee, 1999; English et al., 1995; Sun et al., 2001). Specifically, growth factors
and oxidative stress induce MEKK3/MEK5/ERK5 pathway activation (Chao et al., 1999) and
epidermal growth factor, involved in cellular proliferation, is also mediated through ERK5
signaling (Kato et al., 1998). Leukemia inhibitory factor (LIF), a cardiomyocyte cytokine, has been
demonstrated to activate MEK5, but which occurs independently of MEKK2 and MEKK3
(Nakaoka et al., 2003). Several studies confirm that ERK5 interacts specifically with MEK5 and
not MEK1 or MEK2 (J. D. Lee, Ulevitch, & Han, 1995; G. Zhou et al., 1995). The intracellular
distribution of ERK5 (diffuse vs nuclear) is cell type- and stimulus-specific (Buschbeck & Ullrich,
2005). MEK5-mediated activation of ERK5 occurs following the binding of MEK5’s N-terminus
to the functional domain of ERK5. ERK5 has dual phosphorylation sites in its catalytic domain
that are similar to the binding sites of ERK1 and ERK2 (Kamakura, Moriguchi, & Nishida, 1999;
J. D. Lee et al., 1995; G. Zhou et al., 1995). The C-terminus domain is responsible for regulating
activation, auto-phosphorylation, subcellular localization, and nuclear shuttling of ERK5
throughout the cell. Upon stimulation, ERK5-mediated phosphorylation of its C-terminus induces
conformational changes, which exposes the docking site. ERK5 contains a nuclear localization

21

signaling (NLS) domain (Yan, Luo, Lee, Abe, & Berk, 2001). The conformational change in ERK5
results in an open conformation of ERK5 exposing this NLS domain facilitating its translocation
to the nucleus (Buschbeck & Ullrich, 2005; Kondoh, Terasawa, Morimoto, & Nishida, 2006;
Nishimoto & Nishida, 2006).

After ERK5 is imported into the nucleus, it associates with, phosphorylates, and activates many
transcription factors such as Sap1, c-FOS, c-Myc and MEF2 (Buschbeck & Ullrich, 2005; English
et al., 1999; Kamakura et al., 1999; Kato et al., 1997; Terasawa, Okazaki, & Nishida, 2003; S. H.
Yang, Sharrocks, & Whitmarsh, 2003) eventually regulating cell survival, proliferation, and
differentiation. Transcriptional activation of nuclear transcription factors containing SH3 domains
(Yan et al., 2001) may also occur through an autophosphorylation of and interaction with ERK5’s
proline-rich C-terminus (Buschbeck & Ullrich, 2005; Nishimoto & Nishida, 2006). Transfer of
ERK5 back from the nucleus to the cytosol can occur when the N-terminal half of ERK5 binds to
its C-terminal half (Kondoh et al., 2006; Nishimoto & Nishida, 2006).
1.4. Rationale for studying melatonin’s mechanism of action and MAPK pathways:
As a major signaling pathway, the MEK1/2-ERK1/2 pathway has also been found to be a key
regulatory pathway involved in osteoblast differentiation (Greenblatt, Shim, & Glimcher, 2013).
In mouse osteoblasts, selective expression of constitutively active MAPK/ERK1 accelerates in
vitro differentiation of calvarial cells and in vivo bone development whereas dominant-negative
Mek1 transgenics exhibit low clavicular and calvarial bone mass and hypomineralization (Ge,
Xiao, Jiang, & Franceschi, 2007). The effect of dominant-negative mutants of MEK1 can be
restored following the introduction of constitutively active Mek1 (Ge et al., 2009). Erk1 and Erk2
play essential roles in lineage specification of mesenchymal cells down an osteoblast lineage and
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their inactivation in limb mesenchyme of mice results in low bone mineralization (Matsushita et
al., 2009).

Regarding MEK5 and ERK5 function in osteoblasts, the MEK5-ERK5 pathway was demonstrated
to play more of a prosurvival role, promoting proliferation and suppressing differentiation. For
example, in pre-osteoblastic MC3T3-E1 and bone marrow stromal cells, it was found that the
MEK5-ERK5 pathway promotes osteoblast proliferation and suppresses differentiation
(Kaneshiro, Otsuki, Yoshida, Yoshikawa, & Higuchi, 2015) and plays a role in osteoblast
differentiation (Zhao et al., 2014) and proliferation induced by fluid shear stress (Bo et al., 2016;
P. Li et al., 2012).
As stated previously, melatonin induces osteoblastogenesis and inhibits osteoclastogenesis
through the MAPKs, ERK1/2 (Radio et al., 2006) or ERK5 (S. Maria et al., 2018), in MSCs in
vitro. However, no studies to date report on the role of ERK1/2 and ERK5 on melatonin-mediated
actions on bone density, microarchitecture, and formation providing the rationale for targeting
MEK1/2 and MEK5 in vivo to assess their role in melatonin-mediated actions in bone.
1.5. Hypothesis
Melatonin, through MEK1/2 and MEK5, stimulates osteoblastogenesis and inhibits
osteoclastogenesis to increase bone mineral density, improve bone microarchitecture quality and
strength, and increase bone formation.
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1.6. Specific aims
This study’s research goal involves identifying the role of MEK1/2 and MEK5 on regulating
melatonin-mediated osteoblast and osteoclast differentiation and function in vitro and in vivo, and
to their role in modulating bone density, quality, strength, and formation. To objectively test our
hypothesis, the specific aims include:
1. Assessing the role of MEK1/2 and MEK5 in melatonin–mediated osteoblastogenesis and
osteoclastogenesis and downstream signaling proteins in vitro using small molecule inhibitors of
MEK1/2 and 5 and CRISPR/Cas9 knockout approaches targeting MEK1 or MEK5.
2. Assessing the role of Mek1/2 and Mek5 on melatonin–mediated changes on osteoblast and
osteoclast function in vivo and on bone density, quality, strength, and formation in vivo using
small molecule inhibitors of MEK1/2 and 5 and CRISPR/Cas9 knockout approaches targeting
Mek1 or Mek5 along with histomorphometry and biomechanics analyses.
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Chapter 2: Materials and Methods
2.1. Osteoblast/Osteoclast Co-cultures and MSC Monocultures
2.1.1. Initiation of cell culture
A simple monoculture model was developed using human MSCs (hMSCs; CAT# PT-2501, Lonza,
MD, USA) and mouse mesenchymal stem cells (mMSCs) (kindly donated by Dr. Bruce Bunnell,
from Tulane university, AL,USA). This transwell co-culture model system was used in a previous
study (S. Maria et al., 2018) with slight modification. Specifically, multipotent hMSCs were cocultured

with pre-osteoclasts to

study treatment effects on osteoblastogenesis and

osteoclastogenesis, respectively. For osteoblastogenesis studies, hMSCs and mMSCs were grown
in 75 cm2 cell culture flasks using human mesenchymal stem cell growth medium (Os-) (CAT#
PT-3001, Lonza, USA) and DMEM: F12 media containing 10% fetal bovine serum (FBS) (Gibco,
USA), 1% L-Glutamine (Gibco, USA), and 1% antibiotic-antimycotic (ThermoFisher scientific,
USA) respectively. Cells were maintained at 37°C, 5% CO2 and 90% humidity. When the flask
was 80% confluent, cells were passaged following detachment from the flask surface by phosphate
buffer saline (PBS) without calcium chloride and magnesium chloride (Millipore-sigma) wash,
trypsinization and transferred into other tissue culture plates or flasks.
2.1.2. CRISPR/Cas9 transfection:
CRISPR/Cas9 transfections were performed on hMSCs and mMSCs following the “CRISPR KO
Transfection protocol” using reagents from Santa Cruz Biotechnology, Inc, Texas. The
CRISPR/Cas9 KO plasmid used for transfection enables the identification and cleavage of specific
genes by utilizing guide RNA (gRNA) sequences and by producing a double-strand break (DSB)
within the specific gene causing disruption of gene expression (Cong & Zhang, 2015; Shalem et
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al., 2014). The CRISPR/Cas9 KO plasmid contains gene encoding the Cas9 nuclease and a targetspecific 20 nucleotide (nt) guide RNA (gRNA) for specific gene (i.e., MEK1/Mek1 or
MEK5/Mek5) targeting, and a green florescent protein (GFP) encoding gene, which allows for
visual confirmation of a successful transfection (Santa Cruz Biotechnology, Inc.). Double-strand
breaks (DSB) in DNA can be repaired by either the non-homologous end-joining (NHEJ) or the
homology-directed repair (HDR) pathway. (Cong et al., 2013; Mali et al., 2013; Ran et al., 2013).
The HDR plasmid used in the co-transfection experiments contains an HDR template
corresponding to the cut sites generated by the KO plasmid; this allows for the incorporation of a
puromycin resistance gene into the cells allowing for selection of stable knockout (KO) cells in
cell medium containing puromycin (Santa Cruz Biotechnology, Inc.). As a negative control for the
experiment, a control CRISPR/Cas9 plasmid was used, which contains a non-targeting 20 nt
scramble guide RNA (gRNA) designed not to recognize any DNA sequence and to not bind or
cleave genomic DNA, and a green florescent protein (GFP) encoding gene, which allows for visual
confirmation of a successful transfection (Santa Cruz Biotechnology, Inc.).

Cells were dually transfected with a combination of human MEK5 KO plasmid (sc-401688) and
human MEK5 HDR plasmid (sc-401688-HDR), or combination of human MEK1 KO plasmids (sc400397-KO-2) and human MEK1 HDR plasmids (sc-400397-HDR-2), or combination of mouse
MEK5 KO plasmids (sc-423906) and mouse MEK5 HDR plasmids (sc-423906-HDR), or a
combination of mouse MEK1 KO plasmids (sc-424031) and mouse MEK1 HDR plasmids (sc424031 HDR). This combination was to achieve complete gene knockout (i.e., MEK1KO or
MEK5KO) as well as to incorporate the puromycin-resistant gene to select for dually transfected
MSCs using puromycin-enriched medium. Preliminary studies were conducted to optimize the
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transfection conditions, which were based on the rate of cell growth of the hMSCs and mMSCs
after 24 hours of cell plating, initial cell seeding, cell confluency, transfection efficiency and
cellular toxicity. The optimal plasmid DNA:ultraCruz transfection reagent (sc-395739) ratio for
each well was determined experimentally to be 2 μg of plasmid DNA for KO and HDR plasmids,
1μg of plasmid DNA for control plasmid (sc-418922), and 10 μl of UltraCruz transfection reagent.
Transfections were conducted in a 6-well tissue culture plate where 1.5 x 105 – 2.5 x 105 cells
were seeded and allowed to grow into a 40-80% confluency. Twenty-four hours prior to
transfection, the cell medium was replaced with 3 ml of antibiotic-free standard growth medium
(for hMSCs: MSC basal medium + MSC growth supplement + L-glutamine and for mMSCs:
DMEM:F12 + 10% FBS + 1% L-glutamine) . On the day of transfection, two solutions were
prepared: plasmids in transfection media (sc-108062) (solution A) and transfection reagents in
transfection media (solution B). Both solutions were mixed dropwise and vortexed immediately.
After removing the antibiotic-free standard growth medium from the wells, the A and B mixture
was applied directly on top of the cells in a dropwise manner and the culture plate was incubated
for 1-2 minutes in a cell incubator (5% CO2, 37oC). Next, fresh antibiotic-free standard growth
medium was added to the wells and allowed to incubate for 48 hours. These experimental
conditions were developed to achieve the highest transfection efficiency.

After incubation for 24 hours (of total 48 hours incubation time), successful transfection of
CRISPR/Cas9 KO plasmid was confirmed visually through detection of green fluorescent protein
(GFP) using fluorescent microscopy captured using an EVOSTM inverted light microscope
(ThermoFisher Scientific, Waltham, MA, USA) (Figures 7A, 8A, 12A, 13A). In addition to visual
detection of GFP to confirm transfection of the CRISPR/Cas9 KO and HDR plasmids, 48 hours

27

post transfection, MSCs were exposed to puromycin dihydrochloride antibiotic (2μg/ml; sc108071) containing medium for 3 days to screen for the HDR plasmid-containing MSCs. By this
time, all non-transfected cells were killed, and transfected cells enriched by the puromycin. Cells
were then refed with fresh regular antibiotic-containing medium and allowed to grow for an
additional 3-5 days until confluence after which some of the cells were tested for MEK1 or MEK5
KO by western blot. After confirmation of gene knockout, parallel wells of cells were subjected to
alizarin red staining (hMSCs, mMSCs) or used in the calvarial defect studies described below.
2.1.3. In vitro treatment preparation
In vitro treatment concentrations were calculated based on the doses used in the previous studies
(S. Maria et al., 2018). Melatonin (50nM) (Sigma-M-5250), Luzindole (1mM) (Tocris-0877), 4PPDOT (1mM) (Tocris-1034), BIX02189 (10 mM) (Santa cruz), PD184352 (10 mM) (Santa cruz),
and SC-1-151(10 mM) (generous gift from Dr. Patrick Flaherty) were used as final concentrations
for the experiments described herein. Stocks (10mM) of each of these drugs were prepared by
dissolving them into 100% pure ethanol followed by dilution using medium to achieve the final
concentration of each treatment per well.
2.1.4. Initiation of hMSCs and mMSCs monoculture.
Studies were conducted using transwell cultures containing MSCs and pre-osteoclasts or in MSC
monocultures. For the monoculture studies, MSCs were grown in 6-well or 24-well cell culture
plates (Corning, NY, USA). Cells (knockout, control plasmid containing, and wildtype) were
seeded (at passage 3-5) at same initial density of 3 × 103 cells/cm2 in all wells with a goal to
minimize pipetting error. On the first day of the 21-day treatment, MSCs (mouse or human) were
fed with either basal growth medium (Os-) or osteogenic medium (Os+) (for hMSCs, medium was
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purchased from Lonza, USA, CAT# PT-3002 and for mMSCs, the medium was DMEM:F12
containing L-ascorbic acid (0.1%; Sigma), β-glycerophosphate (4%; Sigma), dexamethasone
(0.01%; Sigma), and FBS (10%). As mesenchymal stem cells can differentiate into osteoblasts,
chondrocytes, myocytes, and adipocytes, osteogenic medium (Os+) was applied to induce the
differentiation of hMSCs into osteoblasts (Langenbach & Handschel, 2013). In the presence of
both medium conditions (Os- and Os+), MSCs were treated with vehicle (veh; 0.001% ethanol
final concentration) or melatonin (mel; 50 nM final concentration). For the antagonist/inhibitor
studies conducted on mMSCs, mMSCs were treated with the non-selective MT1 and MT2
melatonin receptor antagonist, luzindole (1µM final concentration), the MT2 melatonin receptor
antagonist, 4P-P-DOT (1µM final concentration), the MEK5 inhibitor, BIX02189 (10 µM final
concentration), the MEK1/2 inhibitor, PD184352 (10 µM final concentration), and the dual
MEK1/2/5 inhibitor, SC-1-151(10 µM final concentration) and in combination. Full media
changes occurred every 3 to 4 days until day 21, when alizarin red staining was performed (details
in Section 2.2).
2.1.5. Initiation of hMSCs/human preosteoclasts co-culture.
A co-culture model was developed to study melatonin-mediated and mechanisms underlying
osteoblast actions on osteoclast activity by tartrate resistant acid phosphatase (TRAP) and
resorption pit formation analyses (Vesprey & Yang, 2016). For the co-culture studies of hMSCs
and pre-osteoclasts, MSCs (both wildtype and transfected cells) were plated at a density of ~3000
cells/cm2 in the bottom chamber of a 96-well transwell plate (Corning Transwell Permeable
Support 96 plate; Cat# 3381, Corning, USA) and exposed to basal growth medium (Os-) or
osteogenic medium (Os+) containing vehicle or melatonin. The media was changed every 3-4 days
until day 21—the day of endpoint analyses. Instead of isolating peripheral blood monocytes from
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human blood as described previously (S. Maria et al., 2018), human preosteoclasts (OCP; Lonza2T-110) were purchased and plated in the top chamber of the transwell (10,000 cells/well) or on
top of 0.4mm sterilized bone chips (https://boneslices.com) on day 13 in the presence of osteoclast
medium (Lonza-PT-8001). Bone slices were labeled and sterilized in a sterile hood with UV light
the day before the experiment. OCP medium contains 10% FBS, 1% L-Glutamine, 1% Pen/strep,
RANKL (50ng/mL final concentration for the upper chamber) and M-CSF (33ng/mL final
concentration for the upper chamber), which favors osteoclast differentiation. For the upper
chamber, full media changes occurred once every 2 days from day 13-21. Day 13 was selected to
plate OCPs in the upper chamber because past studies using osteogenic medium have shown that
hMSCs start to differentiate into mature osteoblasts between 14 to 21 days (Sethi et al., 2010) and
begin producing substantial amounts of RANKL, and/or OPG (Atkins et al., 2003) to modulate
osteoclastogenesis (Atkins et al., 2003; Boyce & Xing, 2007a, 2007b). The permeable
polycarbonate membrane between the two chambers of the transwell (pore size 0.4μm, 4.26mm
diameter, 0.143 cm2 growth area) allowed for communication between MSCs/osteoblasts and
preosteoclasts/osteoclasts through the release of factors (i.e., RANKL and OPG) into the media
rather than direct cellular contact. On day 21, assays were performed—TRAP and resorption pit
formation assays—on cells grown in the upper chamber to evaluate treatment effects on osteoclast
proliferation, differentiation, and activity (details in Section 2.3).
2.2. Osteoblast differentiation and mineralization
To assess the involvement of MEK1 and MEK5 on melatonin-mediated induction of
osteoblastogenesis, endpoint analyses occurred on day 21. Day 21 was chosen based on previous
findings demonstrating that melatonin induced osteoblast differentiation from MSCs by this
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timepoint under these culture conditions (Sethi et al., 2010). Calcium mineralization was assessed
by alizarin red staining in cells grown in the bottom chamber of cells to assess the state of
maturation of osteoblasts per manufacturer’s instructions. Briefly, osteogenesis was quantified
through extraction of the mineral deposits released by osteoblasts using the osteogenesis assay kit
(CAT#

ECM815,

EMD

Millipore,

MA,

USA).

Quantification

was

conducted

by

spectrophotometric analysis using an Elmer Victor3 1420 Multilabel plate reader (Waltham, MA,
USA) at 405 nm. Concentrations of alizarin red of the samples were calculated from a standard
curve generated from the absorbance (OD) readings of standards using workout 2.0 software
(Waltham, MA, USA). The raw concentrations were either reported directly or normalized against
Os+_Wildtype_Vehicle and compared between groups. In this assay, the concentration of alizarin
red was proportional to osteoblastic mineralization activity.
Besides quantification of calcium mineralization, qualitative analysis by alizarin red staining was
also conducted by first fixing the cells in 10% formaldehyde (room temperature for 15 minutes)
followed by alizarin red staining (0.25-1mL/well; room temperature; 20 minutes; gentle rocking ),
wash (three times, 5 minutes, gentle rocking with deionized water) and visualization using a
Vistavision microscope (VWR International, Allison Park, PA) with a progress C3 camera
(Jenoptik). For mMSCs, these images were then analyzed using NIH “ImageJ” analysis and
alizarin red levels were calculated from the optical density (OD) value and then normalized against
(Os+_Wildtype_Vehicle)-treated cells and compared between groups.
2.3. Osteoclast assays: qualitative and quantitative TRAP assay and resorption pit formation
assay
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2.3.1 Qualitative TRAP assay
To assess whether or not melatonin-mediated induction of osteoblastogenesis inhibited osteoclast
maturation and activity, bone slices that were plated with pre-osteoclasts were taken from the top
chamber of the transwell co-culture plates and qualitative TRAP assays were carried out to visually
confirm differentiated osteoclast on day 21 using the commercially available Acid Phosphatase
Leukocyte assay kit (CAT# 387A, Sigma, USA) per manufacturer’s instructions. Briefly, a few
drops of fixative solution were added onto the slides (1mL/slide) and incubated for 30 sec before
washing with deionized water. Next, diazotized fast garnet GBC solution (1 mL/slide) was applied
and allowed to incubate for 1h in a water bath at 37oC in the absence of light. After 1 hour, bone
slices were rinsed thoroughly with deionized water and then counterstained with hematoxylin for
2 minutes followed by a thorough rinse with alkaline tap water until the blue nuclei of osteoclasts
became visible. Using a Vistavision microscope (VWR international) equipped with a progress C3
camera (Zenoptik), qualitative assessment of the stained osteoclasts was performed to visualize
purple staining, indicating TRAP deposition by mature osteoclasts.
2.3.2. Resorption pit formation assay
Following qualitative TRAP analysis, osteoclastic activity was also assessed by performing
resorption pit formation analyses following the protocol described (Vesprey & Yang, 2016).
Briefly, following microscopic observation of TRAP (+) osteoclasts, cells were removed from the
bone slice by sonication (5-15 minutes in distilled water at 50-60 Hz using a sonicator Glas-col
homogenizing system, Daiger scientific). Bone slices were then stained using 1% toluidine blue
(Acrose organics, AC348600050) in 1% sodium borate (Fischer scientific, 02003997) solution for
4 minutes by carefully placing the bone slice onto the side of the droplet of toluidine blue solution.
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After rinsing with distilled water, bone slices were air dried and then visually examined and
captured with light microscope (Nikon E800) using a 10x lens. Resorption pits were then analyzed
using NIH “ImageJ” software , where optical density (OD) of total view area and total resorption
pit area (random area in each slice separately) were measured. The total areas of resorption pits
were normalized by total view area to measure the OD value in each bone slice. Finally, these data
were normalized against (Os+_Wildtype_Vehicle)-treated cells and compared between groups.

Figure 1: Sample image showing area of resorption pit.
2.3.3 Quantitative TRAP assay
Quantitative TRAP analysis was performed with slight modification according to the protocol
described (Janckila, Takahashi, Sun, & Yam, 2001). TRAP buffer was first prepared, and the pH
was adjusted at 5.5-6.1. Briefly, to prepare the TRAP buffer, naphthol-ASBI phosphate (N-ASBIP) was utilized as a substrate by first dissolving N-ASBI-P (2.5mM) in a solution containing 1%
ethylene glycol monomethyl ether (EGME), 2% NP40, Na-acetate (100mM) and Na-tartrate
(50mM). Cells were lysed with 50mM TRIS (pH 7.4) and then treated with TRAP buffer. A blank
solution containing a similar volume of TRIS and TRAP buffer only was also prepared. Cells were
then scraped and then transferred into a 5mL tube along with the buffer solutions and incubated at
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37°C for 30 min. Reactions were stopped by adding 2.5 mL of 0.1 M NaOH containing 0.05% NP40. All reagents were bought from Millipore-Sigma, USA. Fluorescence readings were taken at
405nm excitation and 515nm emission wavelength (515 filter) using a VICTOR3 1420 multilabel
plate reader (Perkin Elmer). Data were normalized against Os+_Wildtype_Vehicle and compared
between groups.
2.4. In vivo studies
2.4.1. In vivo treatment paradigm
For the small molecule inhibitor studies, 29-32 days old Balb(c) mice were used and allowed to
adapt to a 12:12 light: dark setting with food and water ad libitum. Balb (c) mice were used based
on their melatonin rhythm, which is a short but significant melatonin peak at the middle of the
night (Vivien-Roels et al., 1998). Mice ages 29-32 days old were used because this was the time
when they were still in the process of sexual maturation and active bone development, which was
relevant to our study goals (Bonucci & Ballanti, 2014; Dutta & Sengupta, 2016). After acclimation,
mice were injected (i.p.) daily for 45 days with vehicle (DMSO; 0.01%), melatonin (0.166mg/kg),
BIX02189/Bix02189 (25mg/kg), MEK1/2 inhibitor (PD184352; 25mg/kg) and SC-1-151
(25mg/kg) in the laboratory of Dr. Matt Burow (Tulane University, accredited by the AAALAC)
within an hour of lights off (~6pm). The dose of melatonin, equivalent to ~ 6 mg melatonin/day
for humans, was selected based on previous studies demonstrating efficacy in increasing bone
density in mice (P. A. Witt-Enderby et al., 2012). The doses of the inhibitors were selected based
on findings demonstrating specificity for their respective kinases with safety and pharmacokinetic
profiles allowing for daily dosing (Allen, Sebolt-Leopold, & Meyer, 2003; Drew, Burow, &
Beckman, 2012; Flaherty et al., 2010). On day 45, mice were sacrificed and blood and whole leg
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bones were harvested for endpoint analyses. Whole leg bones were either snap frozen for western
blot analyses or were cleared of muscle and then wrapped in saline-soaked gauze for
microcomputed tomography (microCT) (Dr. Kostas Verdelis, University of Pittsburgh) and
mediolateral three-point bending analyses (Dr. Alejandro Almarza, University of Pittsburgh).
2.4.2. MicroCT Analysis:
Treatment effects on bone density and microarchitecture were assessed on the left femur bone of
mice by microCT imaging carried out in the laboratory of Dr. Kostas Verdelis, (University of
Pittsburgh) using a Scanco VivaCT 40 (Scanco Medical Bruttisellen, Switzerland) system. The
scans (10.5mm voxel size, 55KVp, 0.36 degrees rotation step, 180 degrees angular range, 200ms
exposure per view) were used to reconstruct 3-D structures for each bone and then trabecular and
cortical bone morphology parameters were analyzed. Specifically, femur trabecular bone
microarchitecture, bone volume fraction (bone volume/total volume, BV/TV, unit = %), trabecular
thickness (thickness of trabeculae) (mm), trabecular separation (local thickness of the marrow
space in between trabeculae) (mm), and number of trabeculae (structural unit of trabecular bone
present per lineal mm) (1/mm), SMI- Structural Model Index (change in surface curvature that
occurs as a structure of trabecular bone), trabecular connectivity density (calculated by dividing
the connectivity estimate of trabecular bone by the volume of the bone) (mg/ml), true trabecular
density (1/mm) were measured (Hsu et al., 2016; X. S. Liu, Sajda, Saha, Wehrli, & Guo, 2006).
Cortical bone morphology in the femur was determined by measuring the total cross-sectional area
(TtAr, unit = mm2), cortical area (CtAr, unit = mm2), cortical bone area fraction (CtAr/TtAr), and
cortical thickness (CtTh, unit = mm), porosity, cortical inner perimeter (mm), cortical outer
perimeter (mm), polar moment of inertia (pMOI), maximum moment of inertia, and minimum
moment of inertia. These data were then reported and compared between groups.
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2.4.3. Mediolateral three-point bending test:
Treatment effects on bone strength was conducted using mediolateral three-point bending in the
laboratory of Dr. Alejandro Almarza (University of Pittsburgh) using an Instron 5564 instrument
(Instron, Norwood, MA). The same left femur used for microCT analysis was placed in a fixture
between two 10-mm supports with the anterior side facing upward. At the beginning of the test,
the bone is in an undeformed state and the loading point with a small pre- load (< 1 N) contacts
the bone for bone placement. Load was then progressively increased at 500 mm/minute until the
bone was broken. Load and displacement values were recorded during the test and a load vs
displacement curve was generated to measure whole-bone (structural) mechanical properties.
These values were combined with the bone geometric properties derived from the microCT
analyses to calculate bone material properties such as stiffness and ultimate stress. Breaking load
(ultimate stress), which is the capacity of a structure to withstand loads tending to elongate was
calculated using the formula: Maximum Stress=(Force at break*Length)/(4*0.78*(outer radius^4inner radius^4)/outer radius). Stiffness (Modulus), which is the rigidity of an object — the extent
to which it resists deformation in response to an applied force, was calculated using the Equation:
Modulus=(Force*Length^3)/(48*deflection at break*0.78*(outer radius^4-inner radius^4).
2.5. Western blot
2.5.1. Protein and antibody
In previous studies, melatonin’s osteoblastogenic effects in MSCs occurred through the regulation
of osteogenic proteins (S. Maria et al., 2018; Sethi et al., 2010). To determine if these same
proteins [runt-related transcription factor 2 (RUNX2), integrin β1 (ITGB1), nuclear factor kappa
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B (NFκB), peroxisome proliferator-activated receptors gamma (PPARγ), bone morphogenic
protein (BMP-2), Fos related antigen-1 (FRA-1) glucose transporter type 4 (GLUT4/SLC2A4) and
beta subunit of insulin receptor (IRβ), integrin beta-1 (β- 1 integrin), Type-1 collagen, Betacatenin, osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL),
MEK1, MEK5] were modulated in bone in response to the treatments, western blotting was
performed using the Odyssey Western Blotting Kit IV RD (CAT# 926-31084, Licor Biosciences,
USA). Secondary antibodies included goat anti-rabbit (800nm) and goat anti-mouse (680nm),
which were supplied with the Licor western blotting kit (LI-COR Bioscience, USA). Total protein
analysis was performed following manufacturer’s instructions using Licor 700 total protein stain
(LI-COR Bioscience, USA).
Primary antibodies included rabbit anti-OPG/TNFRSF11B (ab73400, Abcam, USA), rabbit antiRANKL/TNFSF11 (ab9957, Abcam, USA), rabbit anti-RUNX2 (sc10758, Santa Cruz Biotech,
USA), rabbit anti-Integrin β1 (sc8978, Santa Cruz Biotech, USA/ Cell signaling-4706S), rabbit
anti- NFκB (sc298, Santa Cruz Biotech, USA), rabbit anti-PPARγ (sc7196, Santa Cruz Biotech,
USA), rabbit anti-GLUT4 (sc7938, Santa Cruz Biotech, USA), rabbit anti-IRβ (sc711, Santa Cruz
Biotech, USA) and mouse anti-β-actin (926-42212, Licor, USA), rabbit anti BMP-2 ( Abcam14933), rabbit anti-FRA-1 (abcam-65051, Abcam, USA), rabbit anti-Type-1 collagen (abcam34710, Abcam, USA), rabbit anti-Beta-catenin (abcam-16051, Abcam, USA), rabbit anti-MEK5
(AB3184 EMD Millipore, USA), rabbit anti-MEK1(SAB4300537, Sigma, USA), rabbit antiERK5 (33726, Cell signaling, USA) .
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2.5.2. Cell lysate preparation.
For all western blots on cells, lysates were prepared. Briefly, following aspiration of cell culture
media and washing in 1X PBS, 2X Laemmli sample buffer (CAT# 161-0737, BioRad, USA)
containing β-mercaptoethanol (CAT# 161-0710, BioRad, USA) was added at a ratio of 19:1 to
each well. Then after gently scraping the cells, the cell lysate was transferred into vial and heated
for 5 minutes at 95oC, cooled down and stored at -20oC until use.
2.5.3 Bone lysate preparation.
Bone tissue lysates were prepared from the right femur of Balb (c) mice snap frozen following
treatment [45 days daily i.p. injections of vehicle (DMSO), the MEK5 inhibitor, BIX 02189 (25
mg/kg), the MEK1/2 inhibitor, PD184352 (25mg/kg) or the dual MEK1/2 and 5 inhibitor, SC-1151 (25 mg/kg) alone or in combination with melatonin (~0.166mg/kg)]. Briefly, on the day of the
bone lysate preparation, femur bone was first stripped of muscle and then pulverized into powder
using a mortar and pestle under liquid nitrogen. This pulverized bone powder was then scraped
into 2mL of cell lysis buffer [2% SDS, 2M urea, 10% glycerol, 10 mM Tris-HCl (pH 6.8), 10 mM
DTT, and 1 mM PMSF] and homogenized using a tissue tearer (three 10 sec bursts on ice). The
supernatant was collected after centrifugation at 15,000 rpm and then stored at -20°C until use.
2.5.4. SDS-PAGE and western blot analyses
To separate proteins in preparation for western blot analysis, 20-30 μL of cell or bone lysate and
10 μL of molecular weight marker (Precision Plus Protein, CAT# 161-0373, BioRad, USA) were
added to the wells of a 10% SDS-polyacrylamide gel. Proteins were then transferred to
nitrocellulose membranes and placed in blocking buffer to reduce non-specific binding for 1h with
gentle rocking. Membranes were then incubated overnight at 4°C with gentle rocking with the
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respective primary antibodies and western blot control protein antibody (anti-β-actin antibody) to
visualize the proteins of interest and to normalize for protein load. For the total protein assay, the
membrane was treated with total protein stain first before applying blocking buffer and any
primary antibody. Next, blots were washed three times with PBS-tween solution followed by
incubation with secondary antibodies for 45 minutes to 1 hour at room temperature. Protein bands
were visualized using the Odyssey Infrared Imager, the bands were quantified using Odyssey
software (Licor bioscience, USA) and then normalized against β-actin or total protein as needed
to control for variations in protein loading between treatment groups.
2.6. Calvarial Defect Assay
The role of Mek1 and Mek5 in melatonin-induced bone formation was assessed using the
CRISPR/Cas9 method in a mouse calvarial defect model. Mek5 and Mek1 knockout mMSCs
generated using the CRISPR/Cas system were used in the calvarial defect assays conducted in the
laboratory of Dr. Bunnell (Tulane University, accredited by the AAALAC) . Briefly, 29-32 day
old Balb(c) mice (male and female) were used after acclimation. A critical size calvarial defect
was created on the center of right parietal bone in mice under anesthesia. MSCs (wildtype, control,
Mek1KO, Mek5KO) were cultured and initially seeded on sterilized PLGA scaffolds before being
placed into the critical size calvarial defects in Balb(c) mice. The wound was then closed by
suturing and mice were exposed to treatments for 3 months. Mice were given vehicle (0.1%
ethanol) or melatonin (15mg/L) in their drinking water during the night for 90 days. This melatonin
dosage was already studied in mice and showed efficacy in increasing bone density (P. A. WittEnderby et al., 2012). Three and 10 days prior to mice sacrifice, mice were injected with Calcein
to measure bone formation rate. On day 90 and after sectioning and harvesting the bone, the
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calvarial defects were fixed in 4% paraformaldehyde and then sent to the University of Alabama
Core Bone Facility to undergo histological analysis—both static (through Goldner trichrome
staining) and dynamic (on unstained slides) analyses. In trichrome staining, two or more acid dyes
were used in conjunction with a polyacid, which differentiates tissues by tinting them in
contrasting colors (Rentsch, Schneiders, Manthey, Rentsch, & Rammelt, 2014). These histological
differences between tissue types were quantified (observers-blind), normalized against “total tissue
area in defect zone” and then compared between groups. Stratification by gender was also
conducted to study gender effects and hormonal influences in mediating melatonin’s actions on
new bone growth.
2.7. Statistical interpretation
All statistical testing was carried out GraphPad Prism version 8 (GraphPad Software, San Diego,
CA, USA) for Macintosh. Based on the requirement, data analyses were performed by one-way,
two-way, or three-way ANOVA followed by Tukey’s post-hoc multiple comparison t-test, where
significance was defined as p < 0.05. Data represent the mean ± SEM unless mentioned otherwise.
Data points that were determined to be outliers by Grubbs’ test were excluded. All data were either
reported as raw values or normalized against the assay control.
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Chapter 3: Assessment of the role of MEK1/2 and MEK5 on melatonin-mediated actions on
osteoblast and osteoclast differentiation and activity in vitro.
3.1. Background
Physiological bone remodeling is a constant and dynamic process maintained through a steady
balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation
(Raisz & Seeman, 2001). Declines in estrogen, progesterone and testosterone, and increases in
cortisol that occur naturally with the aging process coupled with a lifestyle that produces chronic
oxidative stress and inflammation in the body, contributes to bone loss over time (Boskey &
Coleman, 2010). The hallmark characteristics of aging bone are: 1) reduction in response to bonepromoting stimuli such as vitamin D, growth hormone and IGF-1 (D'Avis P, Frazier, Shapiro, &
Fedarko, 1997; Pfeilschifter et al., 1993); 2) increases in bone marrow adiposity due to reduced
differentiation of mesenchymal stem cells (MSCs) into osteoblasts; and 3) increase in the life span
of mature osteoclasts (G. K. Chan & Duque, 2002). Oxidative stress-induced production of free
radicals and depletion of the body’s antioxidant defenses (Domazetovic, Marcucci, Iantomasi,
Brandi, & Vincenzini, 2017; Wauquier, Leotoing, Coxam, Guicheux, & Wittrant, 2009) can affect
bone remodeling and contribute to the pathogenesis of

osteoporosis by stimulating

osteoclastogenesis and inhibiting osteoblastogenesis (Finkel & Holbrook, 2000; Kadenbach,
Ramzan, & Vogt, 2009).

Melatonin’s bone-favoring effects observed in clinical models (See Chapter 1 Introduction) may
be explained by its stimulatory effects on osteoblasts as demonstrated in numerous studies (W.
Chen et al., 2020; Chu et al., 2017; S. Maria et al., 2018; Nakade, Koyama, Ariji, Yajima, & Kaku,
1999; K. H. Park et al., 2011; Radio et al., 2006; Roth et al., 1999; Sanchez-Hidalgo et al., 2007;
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Sethi et al., 2010; Zaminy et al., 2008; L. Zhang et al., 2010; L. Zhang et al., 2013; W. L. Zhang
et al., 2016), and inhibitory effects on osteoclasts (Histing et al., 2012; Ikegame et al., 2019; H. J.
Kim, Kim, Bae, & Kim, 2017; Koyama, Nakade, Takada, Kaku, & Lau, 2002; Ping et al., 2017;
Suzuki & Hattori, 2002; Y. Zhou et al., 2020), creating a balanced overall bone remodeling
process. Melatonin’s two cognate G-protein coupled receptors, MT1 and MT2, are widely
distributed throughout bodily tissues and cells (Dubocovich & Markowska, 2005; Hill et al., 2015;
Lacoste et al., 2015; Maria S., 2014; Reiter et al., 2007; Suofu et al., 2018; Suofu et al., 2017),
including osteoblasts and osteoclasts (Slominski et al., 2012) and mitochondria (Suofu et al., 2018;
Suofu et al., 2017). From many studies it has been concluded that MT2Rs mediate melatonin’s
actions in osteoblasts and bone (S. Maria et al., 2018; Radio et al., 2006; Sethi et al., 2010; Sharan,
Lewis, Furukawa, & Yadav, 2017). Pretreatment (Mehrzadi et al., 2017; She et al., 2014; F. W.
Wang et al., 2013) or treatment (S. Lee, Le, & Kang, 2018) with melatonin effectively protects
bone marrow-derived MSCs or osteoblast-like cells from oxidative stress-induced toxicity and
attenuates AlCl3 -induced stress effects in MC3T3-E1 cells (Cao et al., 2020) in vitro. Even though
most of the studies have found melatonin’s inhibitory actions on the osteoclast to be indirect, Zhou
et al. reported that at pharmacological concentrations (1‐100 μmol/L), melatonin inhibits
osteoclastogenesis of bone marrow monocytes via a ROS‐mediated pathway (L. Zhou et al., 2017).
A complete summary of melatonin’s actions on bone and bone cells are summarized in table 2.
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Table 2:Role of melatonin in bone remodeling: In vitro findings
In vitro model: Osteoblasts (OB) only
Exogenous/ Direct Melatonin Effect
Induces of osteogenic gene expression and increases osteoblastogenesis
through melatonin receptors in bone cell lines
Increases ALP activity in differentiating hMSCs via MT2 melatonin
receptors and the MEK/ERK1/2 signaling cascade
Increases osteogenic differentiation of BMSC not ADSC via increasing
cell viability of BMSCs
A continuous 21-day Mel exposure induces osteoblastogenesis, which
involves MT₂R/Gi/β-arrestin/MEK/ERK1/2 pathway and induction of
RUNX-2, OCN and BMP-2 expression.
Increases osteoblastic differentiation via BMP/ERK/Wnt pathways

References
(Roth et al., 1999)
(Radio et al., 2006)
(Zaminy et al., 2008)
(Sethi et al., 2010)

(K. H. Park et al.,
2011)
(L. Zhang et al.,
2013)
(Sanchez-Hidalgo et
al., 2007)
(L. Zhang et al.,
2010)

Sustained release of melatonin increases mineralization and osteogenic
marker expression in hMSCs in vitro
Decreases intracellular triglyceride accumulation (adipogenic
differentiation) through melatonin receptor-mediated mechanisms
Inhibits hMSC adipogenic differentiation, enhances osteogenic
differentiation, suppresses PPARγ expression, adipogenic markers
(leptin, lipoprotein lipase, adiponectin, and adipocyte protein 2) and
promotes Runx2 expression, osteogenic markers (ALP, OPN and OCN)
Increases bone formation via increasing proliferation of normal human (Nakade et al., 1999)
bone cells and human osteoblastic cell line and type I collagen synthesis
Reverses of H2O2 ‐induced changes in cytotoxicity (cell death, increased (She et al., 2014)
ROS, MDA) in MG63 osteoblast‐like cell line via reversing disruption of
mitochondrial membrane potential, reduction of mitochondrial DNA
copy number
Attenuates H2O2‐induced MSC apoptosis through melatonin receptormediated suppression of intracellular ROS, phospho‐P38 MAPK, and
Bax/Bcl‐2 expressions, caspase‐3 activation
Increases viability and decreases apoptotic fraction of BM-MSCs by
decreasing ROS, inflammatory cytokines, increase in SOD and CAT
enzymes activity, diminished caspase-3 and Bax expressions
Enhances osteogenic differentiation of hMSCs and restores osteogenesis
activation of AMPK, upregulates of FOXO3a & RUNX2 under oxidative
stress condition
Improves AlCl3-induced osteoblast dysfunction by increasing cell
viability, ALP activity, and type I collagen level, and SOD and
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(F. W. Wang et al.,
2013)
(Mehrzadi
2017)

et

al.,

(S. Lee et al., 2018)

(Cao et al., 2020)

glutathione and RUNX2, osterix expressions and decreasing ROS, p53
expression, 8-hydroxy-2′-deoxyguanosine & apoptosis
In vitro model: Osteoclasts (OC) only
Exogenous/ Direct Melatonin Effect
Decreases RANKL-induced osteoclastogenesis from macrophages via
inhibition of NFκB signaling pathway
Inhibits osteoclast formation dose-dependently by inhibiting NFκB
signaling pathway
Inhibits osteoclastic activation by microgravity by stimulating
calcitonin mRNA, decrease in RANKL mRNA

References
(H. J. Kim et al.,
2017)
(L. Zhou et al., 2017)
(Ikegame
2019)

et

al.,

Mel- Melatonin, RANKL- receptor activator of nuclear factor kappa B ligand, PPARγ- Peroxisome
proliferator-activated receptor gamma, GLUT4- Glucose transporter type 4, ALP- Alkaline phosphatase,
HYP- Hydroxyproline, Ca-Calcium, OB-Osteoblast, Runx2- Runt-related transcription factor 2, Bmp2Bone morphogenic protein 2 , Bmp6- Bone morphogenic protein 6, Bglap- bone gamma-carboxyglutamic
acid-containing protein (osteocalcin), H2O2- Hydrogen-peroxide, TRAP-Tartrate resistant acid
phosphatase, hMSCs- Human mesenchymal stem cells, hPBMCs- Human peripheral blood monocyte,
OPG- osteoprotegerin, ERK1/2- Extracellular signal-regulated kinases 1/2, ERK5- Extracellular signalregulated kinases 5, BMSC/ BMMSC- Bone marrow derived mesenchymal stem cells, ADSC- Adipose
derived mesenchymal stem cells, OPN- Osteopontin, ROS-Reactive oxygen species, MDAmalondialdehyde, MAPK- mitogen activated protein kinases, Bax- Bcl-2-like protein 4, Bcl2- B-cell
lymphoma 2, CAT- Catalase, AMPK- 5' AMP-activated protein kinase, FOXO3a- Forkhead box O3, NFkB- nuclear factor kappa B.

Even though there are many in vitro studies assessing melatonin’s role in bone cell differentiation,
many have been done on monocultures of MSCs/osteoblasts or preosteoclasts/osteoclasts and so
the issue of translatability is always an issue because in the bone microenvironment a close
communication exists between osteoclasts and osteoblasts. In an attempt to mimic the in vivo bone
microenvironment and the relationships more closely between osteoblasts and osteoclasts,
transwell co-cultures containing MSCs and peripheral blood monocytes were used to assess
melatonin’s actions on inducing osteoblastogenesis and osteoclastogenesis, respectively. In Maria
et al., 2017, it was demonstrated that the type of co-culture system (transwell vs direct contact)
dictated their response to melatonin in the presence of selective MEK1/2 and 5 inhibitors, which
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mostly impacted on melatonin-mediated inhibition of osteoclastogenesis. The conclusions of that
work are summarized in Figure 2.

This previous work addressed important mechanisms underlying osteoblast-osteoclast
communication in vitro and also demonstrated that the proteins identified to be involved in
melatonin-mediated induction of osteoblastogenesis and inhibition of osteoclastogenesis were also
found to be similarly regulated in bone such as pERK1/2 and RUNX2 (S. Maria et al., 2018). One
drawback of these studies was the issue of selectivity of the MEK1/2 inhibitor used (i.e.,
PD98059), which may be able to inhibit MEK5 as reported (Drew et al., 2012). Also, although
myriad in vivo studies have been conducted (See Table 4, Chapter 4 for summary) and that Maria
et al. 2018 demonstrated similar actions of melatonin on osteogenic protein expression between
those in osteoblast-osteoclast co-cultures and mouse bone increasing the translatability of these
findings to the clinical condition, these actions of melatonin were merely correlative and not
causative. Therefore, the role of MEK1/2 and 5 on melatonin-mediated actions on osteoblast and
osteoclast differentiation and activity needs to be investigated both in vitro and in vivo
simultaneously using approaches that would result in the selective inhibition against MEK1/2 and
MEK5.

45

Figure 2: Proposed mechanisms underlying melatonin’s actions on osteoblastogenesis and
osteoclastogenesis (used with permission). Melatonin/MT2 melatonin receptor (MT2R)-mediated
differentiation of osteoblasts from MSCs occurs through the activation of both MEK1/2 and MEK5
pathway. Activation of MEK5/pERK5 increases osteogenic protein (RUNX2, NFκB, and GLUT4)
expression. Melatonin/MT2R-mediated induction of MEK1/2/pERK1/2 leads to decreases in
metabolic proteins (PPARγ, GLUT4, and IRβ) shifting MSCs away from adipogenesis and
towards osteoblastogenesis increasing the number of mature osteoblasts capable of secreting
RANKL and OPG to modulate osteoclastogenesis. Melatonin, through its ability to increase OPG
secretion from osteoblasts, can inhibit osteoclastogenesis. Cross talk between MEK1/2 and MEK5
has been demonstrated using a dual MEK1/2 and 5 inhibitor whereby MEK5 can negatively
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regulate and dominate the

MEK1/2 pathway but only when both kinases are inhibited

simultaneously.
3.2. Approach and methodology
3.2.1 Generation of knockout cells
In order to assess the specific roles of the MAPKs, MEK1 or MEK5, on melatonin-mediated
osteoblastogenesis in vitro and bone formation in vivo, MEK1/Mek1 knockout (MEK1/Mek1KO)
or MEK5/Mek5 knockout (MEK5/Mek5KO) hMSCs and mMSCs were generated using the
CRISPR/Cas9 protocol described in Chapter 2 (Materials and Methods) and in Figure 3.

Figure 3: Knockout hMSCs and mMSCs generation process using CRISPR/Cas9 knockout
approach.
After confirmation of MEK1KO and MEK5KO was established (described in Sections 3.3.1 and
3.3.4), hMSCs were cultured either as monocultures or co-cultures to further characterize the role
of the MAPKs, MEK1/2 and MEK5, in modulating osteogenic and metabolic gene and protein
expression. Mouse MSC knockouts, Mek1KO or Mek5KO, were further cultured as monocultures
for two reasons—one was to determine if the actions of melatonin on inducing osteoblastogenesis
in mMSCs were similar to that shown for hMSCs (S. Maria et al., 2018; Radio et al., 2006; Sethi
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et al., 2010) and the second was to culture enough mMSCs (wildtype, control KO, MEK1KO,
MEK5KO) to be seeded on the PLGA scaffolds for the calvarial defect assays described in Chapter
5 Section 5.2.
3.2.2. Monoculture model using knockout hMSCs
Wildtype, control plasmid transfected, MEK1KO and MEK5KO hMSCs were initially plated in a
24-well plate followed by exposure to growth medium (Os-) or osteogenic (Os+) medium. Cells
were then treated with either 0.001% ethanol as vehicle (Veh) or melatonin (50 nM) (Mel). After
21 days of treatment, cells were exposed to alizarin red staining to determine calcium deposition
by mature osteoblasts. Images taken after alizarin red staining were analyzed using NIH “ImageJ”
analysis and alizarin red levels were calculated from the optical density (OD) value and then
normalized against (Os+_Wildtype_Vehicle)-treated cells. Two-way ANOVA analysis was
performed within and between groups to determine the extent of melatonin-mediated osteoblast
differentiation when MEK1 or MEK5 were knocked out compared to vehicle and to wildtype or
MSCs transfected with control plasmid. A schematic representation of this procedure is shown in
Figure 4.

Figure 4: Experimental design for monoculture model using knockout hMSCs.
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3.2.3. Co-culture model using knockout hMSCs and human pre-osteoclasts.
Wildtype, control plasmid transfected, MEK1KO and MEK5KO hMSCs were plated in the bottom
chamber of a 96 well transwell plate and they were exposed to growth medium (Os-) or osteogenic
(Os+) medium containing either 0.001% ethanol as vehicle (Veh) or melatonin (50 nM) (Mel). On
day 13, in the upper chamber on top of bone chips in osteoclast (OC) medium, osteoclasts precursor
(OCP)/pre-osteoclasts were plated at a density of 10000 cells/well. After 21 days of treatment,
bottom chamber cells were exposed to qualitative and quantitative alizarin red staining (method
details in chapter 2) and in the upper chamber to TRAP (method details in chapter 2) or resorption
pit formation analyses (method details in chapter 2) to evaluate treatment effects on osteoblast and
osteoclast differentiation and activity. Concentrations of alizarin red and TRAP enzyme of the
samples and normalized areas of resorption pits were calculated and compared between groups
using two-way ANOVA. A schematic representation of the process is shown in Figure 5.

Figure 5: Experimental design for co-culture model using knockout hMSCs and human preosteoclast.
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3.2.2. Monoculture model using knockout mMSCs
Like hMSCs, wildtype, control plasmid transfected, Mek1KO and Mek5KO mMSCs were plated
in a 24-well plate and then exposed to growth (Os-) or osteogenic (Os+) medium. In presence of
both media, cells were treated with either 0.001% ethanol as vehicle (Veh) or melatonin (50 nM)
(Mel). Moreover, for the mMSC antagonist or inhibitor studies, mMSCs were cultured similarly
as hMSCs except some studies included the MT1 and MT2 melatonin receptor antagonist,
luzindole, the MT2 melatonin receptor antagonist, 4P-PDOT, the Mek5 inhibitor, BIX02189, the
Mek1/2 inhibitor, PD184352, or the dual Mek1/2/5 inhibitor, SC-1-151 alone or in combination.
After 21 days of treatment, alizarin red staining was performed to determine calcium deposition
by mature osteoblasts. Images taken after alizarin red staining were analyzed using NIH “ImageJ”
analysis and alizarin red levels were calculated from the optical density (OD) value. The data were
then normalized against (Os+_Wildtype_Vehicle)-treated cells and two-way and three-way
ANOVA were performed to compare between groups. Figure 6 shows the schematic
representation of this process.

Figure 6: Experimental design of monoculture model using knockout mMSCs.
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3.3. Results
3.3.1. Confirmation of MEK1KO and MEK5KO in hMSCs
As stated previously, the CRISPR/Cas9 approach was taken to knockout MEK1 and MEK5 in both
human and mouse MSCs.

Because the knockout plasmid contains GFP encoding gene,

fluorescence microscopy was used initially to confirm transfection of both plasmids and western
blot analysis was performed to determine if knockout of the MEK1 and MEK5 protein occurred
in human MSCs indicating successful transfection and gene knockout in hMSCs.
Confirmation of MEK1KO in hMSCs: Figure 7A represents green fluorescence protein
(GFP) inside the cells reflecting successful transfection with the MEK1KO plasmid. Followed by
GFP analysis, western blot analysis was performed and Figure 7B demonstrates that when
compared to the control groups [i.e., wildtype; no transfection group (only treated with transfection
reagents; no plasmid); control plasmid group], MEK1 expression was significantly (p<0.05 vs all
groups) reduced almost to background levels in the MEK1KO group, indicating successful MEK1
gene knockout (see appendix 9.1. for bigger full blot image).
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Figure 7: Confirmation of MEK1KO in hMSCs. Following transfection with MEK1
CRISPR/Cas9KO plasmid, MEK1KO status was confirmed by assessing (A) presence of GFP in
the cells, (B) MEK1 expression in wildtype, control, MEK1KO or MEK5KO hMSCs, and (C)
visual observation of representative blot and protein bands. Cell lysates were prepared and MEK1
levels were normalized by total protein level. Data were analyzed by one-way ANOVA followed
by Tukey Multiple Comparisons test (n=4 per group). Each bar represents the mean OD value (±
SEM) reflecting levels of MEK1 for each respective group. Significance was defined as p<0.05.

Confirmation of MEK5KO in hMSCs: Figure 8A represents GFP inside the cells
reflecting successful transfection with the MEK5KO plasmid. Followed by GFP analysis, western
blot analysis was performed and Figure 8B shows that when compared to wildtype, no transfection
(only treated with transfection reagents, no plasmid) or control plasmid group, MEK5 expression
significantly (p<0.05 vs all groups) reduced in MEK5KO group, indicating successful MEK5 gene
knockout (see appendix 9.1. for bigger full blot image).
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Figure 8: Confirmation of MEK5KO in hMSCs. Following transfection with the MEK5
CRISPR/Cas9KO plasmid, MEK5KO status was confirmed by assessing (A) presence of GFP in
the cells, (B) MEK5 expression in wildtype, control, MEK1KO or MEK5KO hMSCs, and (C)
visual observation of representative blot and protein bands. Cell lysates were prepared and MEK5
levels were normalized by total protein level. Data were analyzed by one-way ANOVA followed
by Tukey Multiple Comparisons test (n=4 per group). Each bar represents the mean OD value (±
SEM) reflecting levels of MEK5 for each respective group. Significance was defined as p<0.05.
3.3.2. The effect of MEK1 and MEK5 on melatonin-mediated induction of alizarin red
staining in hMSC monocultures.
In order to assess the impact of MEK1KO or MEK5KO on melatonin-mediated induction of
osteoblastogenesis in hMSCs, alizarin red staining was performed to assess the extent of calcium
mineralization. As shown in Figure 9, hMSC monocultures exposed to osteogenic (Os+) medium
differentiated into osteoblasts as revealed by the presence of alizarin red staining and hMSCs
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grown in growth (Os-) medium did not differentiate into osteoblasts as revealed by the absence of
alizarin red staining (All Os+ groups, *p< 0.05 vs. all Os- groups). Melatonin increased
osteoblastogenesis in both wildtype and MSCs transfected with control plasmid or knockout
plasmid establishing that the control plasmid did not affect the actions of melatonin on inducing
osteoblast differentiation because these effects of melatonin were similar to that of wildtype
MSCs. Next, the effect of MEK1 or MEK5 knockout was investigated to determine if knock-out
of MEK1 or MEK5 in hMSCs blocks melatonin-induced osteoblastogenesis similar to that shown
in the small molecule inhibitor studies using PD98059 or Bix02189 (S. Maria et al., 2018).
Interestingly, knockout of MEK1 (i.e., MEK1KO), but not MEK5 (i.e., MEK5KO) completely
blocked melatonin-induced osteoblastogenesis revealed by decreases in alizarin red staining when
compared to vehicle-exposed cells.
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Figure 9: Effect of melatonin and role of MEK1 and MEK5 on osteoblast-mediated calcium
mineralization in hMSC monocultures. (A) Following 21 days of exposure to vehicle or
melatonin, calcium deposition was evaluated by alizarin red staining in hMSC monocultures. Each
bar represents the mean OD value (± SEM) reflecting concentration of alizarin red for each
respective group normalized against Os+_Wildtype_Vehicle. Data were analyzed by two-way
ANOVA followed by Tukey Multiple Comparisons test (n=3 per group). (B) Representative
images obtained from the qualitative assessment of osteoblast mineralization. Significance was
defined as p<0.05.
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3.3.3. The effect of MEK1 and MEK5 on melatonin-mediated induction of alizarin red
staining in hMSC:preosteoclast transwell co-cultures.
Aa shown in Figures 10 and 11, alizarin red staining indicated successful differentiation of
hMSCs into osteoblasts in the presence of osteogenic (Os+) medium (Figure 10). TRAP and
resorption pit formation analyses indicated successful differentiation of hOCP into osteoclasts in
the presence of osteoclast (OC) medium (Figure 11) when grown together as co-cultures.

Effect of MEK1 or MEK5 knock-out on melatonin-mediated induction of hMSC differentiation
into osteoblasts in the bottom chamber of the transwell co-culture model.
The extent of calcium mineralization was measured in the bottom chamber of the co-culture
after 21 days of exposure to medium (Os- or Os+) or treatments (vehicle or melatonin). As shown
in Figure 10, hMSCs exposed to osteogenic medium (Os+) compared to growth medium (Os-)
differentiated into osteoblasts (All Os+ groups *p< 0.05 vs. all Os group) as revealed by the
absence of alizarin red staining in all Os- groups. Melatonin increased osteoblastogenesis in both
wildtype and MSCs transfected with control plasmid indicating that the control plasmid did not
interfere with melatonin-mediated signal transduction in differentiating osteoblasts. Knock-out of
either MEK1 (i.e., MEK1KO) or MEK5 (i.e., MEK5KO) completely blocked melatonin-mediated
induction of osteoblastogenesis revealed via decreases in alizarin red staining back to vehicle
levels. Statistical analysis by two-way ANOVA revealed that there was an overall media and
kinase effect, melatonin effect, and significant interaction between melatonin and the kinases.
These data demonstrate that although the osteogenic medium impacted on MEK1 and MEK5
kinase activity, there was a unique interaction between melatonin and the kinases as hMSCs
differentiated into osteoblasts.
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Figure 10: Effect of melatonin and role of MEK1 and MEK5 on osteoblast-mediated calcium
mineralization in hMSCs-hOCP transwell co-culture. On day 21, the extent of calcium
deposition was measured via alizarin red staining in transwell co-cultures treated with medium
(Os- or Os+) or treatments (vehicle or melatonin). Each bar represents the mean (± SEM)
concentration of alizarin red (in μmol/L) for respective groups. Data were analyzed by two-way
ANOVA followed by Tukey Multiple Comparisons test (n=3 per group). Significance was defined
as p<0.05.
Effect of MEK1 or MEK5 knock-out in hMSCs and their impact on the differentiation of preosteoclast into mature osteoclasts in the upper chamber of the transwell co-culture model.
As illustrated in Figure 11, TRAP enzyme release and resorption pit formation was assessed in
the upper chamber of each transwell containing pre-osteoclasts plated on top of bone chips and
following an 8-day co-culture with osteoblasts and their treatments. Figure 11A demonstrates
TRAP release from osteoclasts (OC) in the upper chamber in the presence of osteoblasts (OBs) or
hMSCs (bottom chamber of transwell), treated with melatonin. As shown, the osteoclast media
itself stimulated osteoclastogenesis revealed by the findings that TRAP release still occurred even
in the absence of hMSCs or OB in the bottom chamber. The presence of mature OBs (Os+ exposed)
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but not hMSCs (Os- exposed) was found to be required for melatonin-mediated inhibition of
osteoclastogenesis. This is supported by the findings that MSCs cultured in growth (Os-) medium,
which merely causes MSCs to proliferate but not differentiate into osteoblasts, did not demonstrate
any melatonin-mediated changes in TRAP when compared to MSCs cultured in osteogenic (Os+)
medium, which does induce osteoblastogenesis. Interestingly, decreases in TRAP were observed
when pre-osteoclasts were co-cultured with MSCs (compare bottom chamber with no MSCs vs
bottom chamber with MSCs) indicating that the presence of MSCs inhibits osteoclast
differentiation (Figure 11A). We found that similar to the results in Fig 11A, the ability of
melatonin to inhibit osteoclastogenesis in the co-cultures required osteoblastic differentiation of
both wildtype MSC and control plasmid-containing MSC (Figure 11B). Analysis of the role of
MEK1 or MEK5 knock-out in osteoblasts on melatonin-mediated osteoclast differentiation in cocultures demonstrated that both MEK1 and MEK5 expressed in osteoblasts but not
undifferentiated hMSCs are essential for melatonin’s inhibitory actions on osteoclasts (Figure
11B). Although the resorption pit assays did not reveal significant inhibitory actions of melatonin
on osteoclast activity like the TRAP analysis (Figures 11C, D), trends towards melatoninmediated decreases in osteoclast activity were observed when osteoblasts contained intact MEK1
or MEK5 (Figure 11C), Another important finding from these studies was the importance of
mature osteoblasts (vs MSCs) on regulating the extent of osteoclast differentiation. Presence of
hMSCs inhibited osteoclast differentiation. As shown in Figures 11A and C, significantly higher
levels of osteoclast differentiation and activity occurred when osteoblasts were cultured in
osteogenic (Os+) medium than in growth (Os-) medium. The statistics (i.e., two-way ANOVA)
revealing an overall medium and kinase effect, melatonin effect, but no significant interaction
between melatonin and the kinases also supports this idea. These data also support the idea that
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melatonin is producing its inhibitory effect on osteoclastogenesis indirectly via its actions on
osteoblastogenesis via MEK1 or MEK5. Figure 11D, which depicts pictures of resorption pits that
resulted following exposure to the different treatments, reveals that the area of the resorption pit
was higher in group when osteoclasts were co-cultured with mature osteoblasts. Two-way
ANOVA revealed an overall medium and kinase effect, but no significant melatonin effect or
significant interaction between melatonin and the kinases (see appendix 9.2. for three-way
ANOVA).
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Figure 11: Effect of melatonin and role of MEK1 and MEK5 on osteoclast-mediated TRAP
enzyme release and resorption pit formation in hMSCs-hOCP transwell cocultures. On day 21,
8 days following osteoclast precursor plating, TRAP enzyme release and resorption pit formation
were measured in pre-osteoclasts grown in the upper chamber of the transwell via quantitative
TRAP staining and resorption pit formation assay, respectively. Data were analyzed to determine
(A) The effect of melatonin and osteoblasts on TRAP release from osteoclasts, (B) TRAP
expression by differentiated osteoclasts in different groups, and (C) Resorption pit formation
activity in different groups by mature osteoclasts following exposure to vehicle or melatonin. Each
bar represents the mean (± SEM) of TRAP (fluorescence reading at 405 nm ex, 515 nm em) or
resorption pit area for each respective groups normalized against Os- _Wildtype_Vehicle. Data
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were analyzed by two-way ANOVA followed by Tukey Multiple Comparisons test (n=3 per
group). Significance was defined as p<0.05.
3.3.4. Confirmation of Mek1KO and Mek5KO in mMSCs
Similar to the hMSCs, the CRISPR/Cas9 approach was taken to knockout Mek1 and Mek5 in
mouse (m) MSCs (mMSCs). Because the knockout plasmid contains GFP encoding gene,
fluorescence microscopy was used initially to confirm transfection of both plasmids and western
blot analysis was performed to determine if knockout of the MEK1 and MEK5 protein occurred
in mMSCs to indicate successful transfection and gene knockout in mMSCs.
Confirmation of Mek1KO in mMSCs: Figure 12 represents green fluorescence protein
(GFP) inside the cells reflecting successful transfection with the Mek1KO plasmid. Followed by
GFP analysis, western blot analysis was performed. Figure 12A shows that after the protein bands
were normalized by beta actin, when compared to wildtype, no transfection (only treated with
transfection reagents, no plasmid) or control plasmid group, Mek1 expression was reduced. Mek5
levels were also assessed to study whether knocking out Mek1 impacted on Mek5 expression.
Representative Mek5, Mek1 and beta actin bands, depicted in Figure 12B, were quantified, and
subjected to statistical analysis by one-way ANOVA. Figure 12C demonstrates that when
compared to wildtype, control plasmid or Mek5KO mMSCs, Mek1 expression was significantly
(p<0.05 vs all groups) reduced in Mek1KO mMSCs, indicating successful and selective Mek1
knockout.
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Figure 12: Confirmation of Mek1KO in mMSCs. Following transfection with Mek1
CRISPR/Cas9KO plasmid, Mek1KO status was confirmed by assessing the (A) presence of GFP
in the cells, (B) beta actin and Mek1 bands by western blot, and (C) Mek1 expression in wildtype,
control, Mek1KO or Mek5KO mMSCs. Cell lysates were prepared and Mek1 expression was
normalized by beta actin. Data were analyzed by one-way ANOVA followed by Tukey Multiple
Comparisons test (n=4 per group). Each bar represents the mean OD value (± SEM) reflecting
levels of Mek1 for each respective group.

Confirmation of Mek5KO in mMSCs: Figure 13 represents GFP inside the cells reflecting
successful transfection with the Mek5KO plasmid. Followed by GFP analysis, western blot
analysis was performed. Figure 13A shows that after the protein bands were normalized by beta
actin, when compared to wildtype, no transfection (only treated with transfection reagents, no
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plasmid) or control plasmid group, Mek5 expression was reduced. Mek1 levels were also assessed
to study whether knocking out Mek1 impacted on Mek5 expression. Representative Mek5, Mek1
and beta actin bands, depicted in Figure 13B, were quantified, and subjected to statistical analysis
by one-way ANOVA. Figure 13C demonstrates that when compared to wildtype, control plasmid
and Mek1KO mMSCs, Mek5 expression was significantly (p<0.05 vs all groups) reduced in
Mek5KO mMSCs, indicating successful and selective Mek5 knockout.

Figure 13: Confirmation of Mek5KO in mMSCs. Following transfection with Mek5
CRISPR/Cas9KO plasmid, Mek5KO status was confirmed by assessing (A) the presence of GFP
in the cells, (B) beta actin and Mek5 bands by western blot, and (C) Mek5 expression in wildtype,
control, Mek1KO or Mek5KO mMSCs. Cell lysates were prepared and Mek5 levels were
normalized by beta actin. Data were analyzed by one-way ANOVA followed by Tukey Multiple

63

Comparisons test (n=4 per group). Each bar represents the mean OD value (± SEM) reflecting
levels of Mek5 expression for each respective group.
3.3.5.

Assessing

the

role

of

MT2

melatonin receptors

in

melatonin-mediated

osteoblastogenesis in mouse MSCs.
To determine if melatonin, through melatonin receptors and specifically through MT2Rs, induced
osteoblastogenesis in mMSCs similar to what has been demonstrated in hMSCs, alizarin red
staining was performed in mMSC monocultures exposed to melatonin in the absence or presence
of the melatonin receptor antagonists, luzindole (non-selective MT1R/MT2R antagonist) or 4P-PDOT (selective MT2R antagonist). Similar to hMSCs, exposure to osteogenic (Os+) medium
significantly enhanced osteoblast differentiation revealed by significant (*p<0.05) increases in
alizarin red staining in all Os+ groups compared to mMSCs exposed to growth (Os-) medium
(Figure 14A). The addition of melatonin to Os+ enhanced osteoblast differentiation compared to
vehicle (Figure 14A). Treatment with the melatonin receptor antagonists, luzindole (Figure 14B)
or 4P-PDOT (Figure 14C) blocked the melatonin–mediated increases in osteoblastogenesis
suggesting the involvement of MT2Rs. In all cases, mMSCs transfected with control plasmid were
similar to wildtype mMSCs establishing that the control plasmid did not affect the actions of
melatonin on induced osteoblast differentiation. These assays was critical for establishing the
experimental framework for the calvarial defect assays and served two additional purposes—the
first purpose was to demonstrate that the mMSCs responded similarly to melatonin and worked
through the same mechanisms of action as the hMSCs increasing the translatability of the findings
to the human condition and second to be able to extrapolate the findings determined in vitro to
those observed in vivo in Balb(c) mice.
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Figure 14: Effect of melatonin and melatonin receptors in osteoblast differentiation from
mMSC monocultures. (A) On day 21 of the treatment, calcium deposition by differentiated
osteoblasts was measured via alizarin red staining in mMSCs exposed to melatonin alone or (B)
or in the presence of melatonin receptor antagonists, luzindole or (C) or 4P-P-DOT. Data were
analyzed to determine if melatonin’s actions on mMSC differentiation into osteoblasts was similar
to those observed in hMSCs and to determine if melatonin receptors, specifically MT2Rs,
mediated these actions of melatonin also similar to what was observed in hMSCs. Each bar
represents the mean (± SEM) OD value reflecting the concentration of alizarin red for the
respective group normalized against Os+_Wildtype_Vehicle. Data were analyzed by two-way or
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three-way ANOVA followed by tukey multiple comparison test (n=3 per group). Significance was
defined as p<0.05.
3.3.6. Determination of the actions of melatonin, melatonin receptors and MEK1/2 on
melatonin-mediated induction of osteoblastogenesis in mMSCs.
To study the role of the Mek1/2 pathway or Mek1 specifically in modulating melatonin-mediated
osteoblastogenesis in mMSCs, inhibition of Mek1/2 using the small molecule inhibitor,
PD98059/PD) or CRISPR/Cas9 knockout of Mek1 (Mek1KO) were used, respectively. Both
pharmacological inhibition via PD98059 or knockout of Mek1 by CRISPR/Cas9 were employed
to compare and extrapolate the findings in mMSCs to those observed in vivo in Balb(c) mouse
bone (femur or calvaria). As shown in Figure 15A, inhibition of Mek1/2 by PD98059 or knockout
of Mek1 by CRISPR/Cas9

attenuated Os+ induced and blocked melatonin/Os+ induced

osteoblastogenesis in mMSCs. These findings suggest that Mek1 (and possibly Mek2) are
involved in Os+ induced mMSC differentiation into osteoblasts “in general” [compare higher
alizarin red staining in Os+ wildtype (vehicle or melatonin) vs lower levels observed in Os+
Mek1KO or Mek1/2 inhibition (vehicle or melatonin)] and also involved in melatonin-mediated
actions in mMSC differentiation into osteoblasts [compare Os+ wildtype vehicle vs melatonin
(increase) to Os+/Mek1KO or Os+/Mek1/2 inhibition vehicle vs melatonin (no increase)].
Next, to determine if melatonin receptors worked in parallel to or directly with the MAPK
pathways to induce osteoblastogenesis from mMSCs, melatonin receptor antagonists, luzindole or
4P-P-DOT, were added in combination with melatonin in Mek1KO mMSCs or in combination
with PD98059 (Mek1/2 inhibitor). As shown in Figures 15B and 15C, no further inhibition of
alizarin red staining occurred when luzindole was added along with Mek1KO mMSCs (compare
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Os+/luzindole wildtype to Mek1KO) (Figure 15B) or when 4P-P-DOT was added along with
Mek1KO mMSCs (compare Os+/4P-P-DOT wildtype to Mek1KO) (Figure 15C). Two and threeway ANOVA demonstrates an overall significant media/treatment condition effect, melatonin
effect, kinase (Mek1) effect, luzindole effect, 4P-PDOT effect, and significant interaction between
melatonin and luzindole and melatonin and 4P-PDOT suggesting that melatonin, through MT2Rs,
modulates osteoblastogenesis via Mek1 in mMSCs.

Figure 15: Effect of melatonin, melatonin receptors, and Mek1 on osteoblast differentiation
from mMSC monocultures. (A) On day 21 of the treatment, calcium deposition was measured
via alizarin red staining in mMSC (wildtype or Mek1KO) monocultures exposed to growth (Os-)
or osteogenic (Os+) medium in the presence of melatonin and/or the MEK1/2 inhibitor, PD98059,
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(B) osteogenic (Os+) medium containing melatonin and/or the melatonin receptor antagonist
luzindole or (C) 4P-P-DOT. Data were analyzed to determine if melatonin’s ability to induce
osteoblastogenesis from mMSCs was through MT2Rs that lay upstream of Mek1. Each bar
represents the mean (± SEM) OD value reflecting the concentration of alizarin red for the
respective group normalized against Os+_Wildtype_Vehicle. Data were analyzed by two-way or
three-way ANOVA followed by tukey multiple comparison test (n=3 per group). Significance was
defined as p<0.05.
3.3.7. Determination of the actions of melatonin, melatonin receptors and Mek5 on
melatonin-mediated induction of osteoblastogenesis in mMSCs.
To study the role of the Mek5 pathway or Mek5 specifically in modulating melatonin-mediated
osteoblastogenesis in mMSCs, inhibition of Mek5 using the small molecule inhibitor,
BIX/Bix02189 or CRISPR/Cas9 knockout of Mek5 (Mek5KO) were used, respectively. Both
pharmacological inhibition via Bix02189 or knockout of Mek5 by CRISPR/Cas9 were employed
to compare and extrapolate the findings in mMSCs to those observed in vivo in Balb(c) mouse
bone (femur or calvaria). As shown in Figure 16A, inhibition of Mek5 by Bix02189 or knockout
of Mek5 by CRISPR/Cas9

attenuated Os+ induced and blocked melatonin/Os+ induced

osteoblastogenesis in mMSCs. These findings suggest that Mek5 is involved in Os+ induced
mMSC differentiation into osteoblasts “in general” [compare higher alizarin red staining in Os+
wildtype (vehicle or melatonin) vs lower levels observed in Os+ Mek5KO or Mek5 inhibition
(vehicle or melatonin)] and also involved in melatonin-mediated actions in mMSC differentiation
into osteoblasts [compare Os+ wildtype vehicle vs melatonin (increase) to Os+/Mek5KO or
Os+/Mek5 inhibition vehicle vs melatonin (no increase)].
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Next, to determine if melatonin receptors worked in parallel to or directly with the MAPK
pathways to induce osteoblastogenesis from mMSCs, melatonin receptor antagonists, luzindole or
4P-P-DOT, were added in combination with melatonin in Mek5KO mMSCs or in combination
with Bix02189 (Mek5 inhibitor). As shown in Figures 16B and 16C, no further inhibition of
alizarin red staining occurred when luzindole was added along with Mek5KO mMSCs (compare
Os+/luzindole wildtype to Mek5KO) (Figure 15B) or when 4P-P-DOT was added along with
Mek5KO mMSCs (compare Os+/4P-P-DOT wildtype to Mek5KO) (Figure 15C). However, in
wildtype mMSCs exposed to Os+, a significant decrease in alizarin red staining occurred between
Mek5KO and mMSCs exposed to the Mek5 inhibitor (Bix02189), indicating that Bix02189 may
be inhibiting Mek1/2 as well. Two and three-way ANOVA demonstrates an overall significant
media/treatment condition effect, melatonin effect, kinase (Mek5) effect, luzindole effect, 4PPDOT effect, and significant interaction between melatonin and luzindole and melatonin and 4PPDOT suggesting that melatonin, through MT2Rs, modulates osteoblastogenesis via Mek5 in
mMSCs.
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Figure 16: Effect of melatonin, melatonin receptors, and Mek5 on osteoblast differentiation
from mMSC monocultures. (A) On day 21 of the treatment, calcium deposition was measured via
alizarin red staining in mMSC (wildtype or Mek5KO) monocultures exposed to growth (Os-) or
osteogenic (Os+) medium in the presence of melatonin and/or the MEK5 inhibitor, Bix02189, (B)
osteogenic (Os+) medium containing melatonin and/or the melatonin receptor antagonist luzindole
or (C) 4P-P-DOT. Data were analyzed to determine if melatonin’s ability to induce
osteoblastogenesis from mMSCs was through MT2Rs that lay upstream of Mek5. Each bar
represents the mean (± SEM) OD value reflecting the concentration of alizarin red for the
respective group normalized against Os+_Wildtype_Vehicle. Data were analyzed by two-way or
three-way ANOVA followed by tukey multiple comparison test (n=3 per group). Significance was
defined as p<0.05.
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3.4. Discussion
Melatonin, through its interaction with MT2R activates MEK1 and MEK5 in human osteoblasts,
and thus modulates osteoclast differentiation as revealed through TRAP and potentially resorption
pit analyses. These actions of melatonin occur through MEK1 and MEK5 and are dependent upon
the culturing conditions (Os- vs Os+) suggesting that a communication between differentiating
osteoblasts and osteoclasts through the release of secretory factors (e.g., RANKL and OPG) may
be occurring to direct osteoclastogenesis. Although little is known regarding melatonin’s effect on
osteoclasts, melatonin was found to produce an inhibitory effect on RANKL-mediated
osteoclastogenesis possibly through increasing mRNA and protein expression of OPG (RANKL
decoy receptor) in osteoblasts (Koyama et al., 2002; S. & A., 2014). Except for the effect of Mek1
or Mek5 inhibition alone on osteoblastogenesis, which was without effect in human
osteoblastogenesis and inhibitory in mouse osteoblastogenesis, the studies in mMSCs demonstrate
similar effects of melatonin when compared to hMSCs summarized in Table 3. This was an
important finding because these mMSCs (wildtype, control, Mek1KO and Mek5KO) were used in
the calvarial defect assessing melatonin/Mek1- or melatonin/Mek5- induced actions on bone
formation in vivo, which enhances the translatability of the in vivo findings in Balb(c) mice (male
or female) to the human condition.
Table 3: Summary of findings on melatonin-induced mouse and human osteoblastogenesis
using small molecule inhibitors against MEK1/2 or 5 and CRISPR/Cas9 knockout of Mek1
or Mek5.
Parameters
Medium (Os+) effect

Osteoblastogenesis (compared to vehicle)
Human

Mouse (monoculture)

increased

increased
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Luzindole
(MT1R/MT2R
antagonist) effect

No effect

No effect

Luzindole + Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

4P-P-DOT
effect
(MT2R antagonist)

No effect

No effect

4P-P-DOT+ Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

MEK1/2 or Mek1/2
inhibition alone

No effect

Decreased

MEK1/2 or Mek1/2
inhibition + Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

MEK5
or
Mek5
inhibition alone

No effect

Decreased

MEK5
or
Mek5
inhibition + Melatonin

Did not block Mel’s effect in monoculture
but blocked Mel’s effect in co-culture

Blocked Mel’s effect

The findings in mMSCs described in this study are similar to what has been discovered in mouse
osteoblastic cell lines demonstrating the involvement of the Erk1/2 signaling pathway on
proliferation and differentiation (Raucci, Bellosta, Grassi, Basilico, & Mansukhani, 2008). The
fact that PD98059 or Bix02189 alone inhibited Os+ medium induced osteoblastogenesis in mouse
but not human MSCs suggest that some inherent variation between the mouse and human skeletal
system exists such as continuous growth even after puberty and lack of osteonal remodeling of
cortical bone (unlike human) (Jilka, 2013). There is evidence that both mouse and human bone
marrow cells are capable of de novo synthesis of melatonin (Conti et al., 2000). Although
melatonin’s osteoblast-promoting effect mediated through melatonin receptor has been reported
before in mouse pre-osteoblast and osteoblast cell lines (K. H. Park et al., 2011; Roth et al., 1999),
this is the first study reporting the specific involvement of MT2Rs. Park et al. reported the
involvement of the BMP/ERK/Wnt signaling pathway in melatonin-mediated mouse osteoblast
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differentiation, using PD98059, a Mek1/2 and not Mek5 inhibitor (K. H. Park et al., 2011). In this
study, the use of specific Mek1/2 and Mek5 inhibitors and even more specific gene knockout
approaches helped to further delineate the roles of Mek1/2 and Mek5 in mouse osteoblastogenesis
in vitro and bone in vivo.
From the human co-culture studies, it was observed that the mere presence of osteogenic (Os+)
medium does not produce any effect on osteoclasts, which is similar to that was reported by
H.C.Park et al. as osteoclasts cultured in osteogenic conditioned medium did not differentiate into
osteoclasts, but only differentiated when co-cultured with pre-osteoblasts or mature osteoblasts
(H. C. Park et al., 2017). This is expected as mature osteoblasts (not hMSCs) can regulate
osteoclastogenesis via regulating OPG:RANKL ratio (Boyce & Xing, 2007b) and that melatonin
treatment can also modulate the ratio of OPG:RANKL ratio (S. Maria et al., 2018). This
OPG:RANKL ratio-mediated regulation of osteoclastogenesis can also be predicted in mice, as at
micromolar doses, melatonin decreases the expression of RANK mRNA and increases both the
mRNA and protein levels of OPG in mouse osteoblasts (Koyama et al., 2002).
In summary, in both human and mouse MSCs, melatonin’s effect on osteoblastogenesis was
occurring strictly through MT2R-mediated actions on MEK5 and/or MEK1 and not through an
indirect action of melatonin on MEK5 or MEK1. This claim is supported by the data showing that
no additional inhibitory actions on melatonin-mediated osteoblastogenesis occurred when
MEK5KO or MEK1KO MSCs were combined with luzindole or 4-P-PDOT. Moreover, no
interaction was found between the kinases and antagonists even though significant effects were
found for: melatonin, MEK5, luzindole, 4-P-PDOT; and an interaction was observed between
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medium (Os- vs Os+) and treatment; and between melatonin and the antagonists, luzindole and
4P-P-DOT by three-way ANOVA.
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Chapter 4: Assessment of the role of MEK1/2 and 5 on melatonin-mediated actions on
histomorphometry and biomechanical properties of bone using small molecule inhibitors.
4.1. Background
The normal bone turnover process regulates calcium balance, repairs microscopic cracks sustained
during normal activity, and heals fractures (C. M. Swanson et al., 2018). Age-associated bone loss
may be due to an imbalance in osteoblast and osteoclast activity and this may be due to decreases
in bone-protecting hormones [i.e., melatonin, estrogen, progesterone, and testosterone (Al-Azzawi
& Palacios, 2009; Iguichi et al., 1982)] and increases in hormones (i.e., cortisol) known to break
down bone (C. M. Swanson et al., 2018; Yiallouris et al., 2019). These imbalances in the bone
remodeling over time may result in resorption-mediated changes in bone quality (e.g.,
microarchitecture changes like ↓ trabecular number and thickness, ↑ spacing) and mechanical
properties (e.g., ↓ bone stiffness and ultimate stress) (G. K. Chan & Duque, 2002). Out of the two
bone types, cortical bone and trabecular bone, cortical bone is mainly lost through subendosteal
resorption and trabecular bone through repeated perforations (loss of trabeculae in the trabecular
bone) (Amstrup et al., 2013), contributing to fragile bones and increased risk of stress zones and
fractures (Ensrud & Crandall, 2017).
Melatonin is primarily known for its role in circadian entrainment for being the primary circadian
output marker released from the brain (Pevet & Challet, 2011). As light inhibits and darkness
stimulates melatonin synthesis and secretion from the pineal gland, melatonin synchronizes the
whole organism and peripheral clocks to the light: dark cycle aligning physiological processes to
enhance the health and survival of the organism. For example, melatonin levels are highest in
humans during sleep facilitating bone metabolic processes to ensure maximal bone remodeling
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(Greenspan et al., 1997; Hardeland, Madrid, Tan, & Reiter, 2012; Hassager et al., 1992; Heshmati
et al., 1998; S. Maria & Witt-Enderby, 2014; Ostrowska, Kos-Kudla, Marek, et al., 2003). By
contrast, in nocturnal rodents, bone metabolism and melatonin levels are high when the animal is
most active most likely adopting nighttime foraging behaviors to enhance their survival from
predators (T. Liu & Borjigin, 2006). Even though differences exist between humans and rodents
in this respect, melatonin has demonstrated bone-protective or BMD-enhancing actions in various
models. Specifically, adverse bone effects occurred in rodents (Ostrowska, Kos-Kudla, Marek,
et al., 2003) or other animal models (sheep, chicken, Atlantic salmon) whose endogenous
melatonin levels were decreased by pinealectomy (Egermann et al., 2011; Fjelldal et al., 2004;
Kono et al., 2011; Machida et al., 1995; Ostrowska, Kos-Kudla, Nowak, et al., 2003; Turgut et al.,
2005) or constant light (Ostrowska, Kos-Kudla, Marek, et al., 2003), which was then restored when
melatonin supplementation was given. Also, melatonin-mediated increases in BMD occurred
when melatonin was given exogenously (Koyama et al., 2002; Palin et al., 2018; Sharan et al.,
2017; Tresguerres et al., 2014; Uslu et al., 2007; P. A. Witt-Enderby et al., 2012) (Table 4). When
compared to an estrogen and progesterone hormone therapy, melatonin demonstrated equal
efficacy at increasing BMD in Her2/neu female mice (P. A. Witt-Enderby et al., 2012). By
affecting bone microstructure and biomechanical properties, dietary melatonin supplementation
improves age-related bone loss in old rats (Tresguerres et al., 2014).
Although it has been demonstrated in numerous studies that melatonin’s bone-enhancing
mechanism of action involves melatonin receptors and GPCR-coupled pathways, melatonin also
possesses strong antioxidant and free radical scavenging properties., which may work through this
mechanism to protect against bone loss mediated through oxidative stress. Melatonin has been
shown to neutralize free radicals (Poeggeler et al., 1993), increase antioxidant enzymes like
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superoxide dismutase (SOD) (Inal et al., 2001) and molecules like glutathione (Winiarska et al.,
2006) and prevent electron leakage from the mitochondria and electron transport chain (Leon et
al., 2005). Melatonin has been demonstrated to ameliorate the deterioration of bone quality in rat
femur by oxidative stress triggered by radiation exposure (Cakir et al., 2016) and increase bone
mass accrual around prostheses by maintaining oxidative homeostasis and mitochondrial function
in ovariectomized (OVX) rats (W. Zhou et al., 2019). Melatonin administration also possesses
beneficial effects on short‐term bone formation and healing (Yildirimturk et al., 2016) and
improves alveolar bone loss (Kose et al., 2016) in diabetic rats—a model and disease associated
with oxidative stress. Other actions of melatonin against oxidative stress-related bone loss include
1) increasing sirtuin 1 (SIRT1)—a protein that promotes cell survival by inhibiting apoptosis or
cellular senescence on bone marrow-derived MSCs from OVX rats (Amstrup et al., 2013;
Aravamudhan et al., 2013; Luchetti et al., 2014; Vriend & Reiter, 2016), 2) scavenging reactive
nitrogen species (Crespo et al., 1999; Gilad et al., 1998) to attenuate the adverse effects of oxidative
stress on the skeletal system (Y. H. Chen et al., 2006; Oktem et al., 2006), and 3) reversing
oxidative stress-induced fetal skeleton deformities in pregnant dams (Y. H. Chen et al., 2006).
The inflammatory cytokines, IL-1 (Pacifici et al., 1989; Wei, Kitaura, Zhou, Ross, & Teitelbaum,
2005) and TNF-α (Moffett et al., 2005; Romas, Gillespie, & Martin, 2002) ) can impair bone
formation through an amplification of osteoclast-mediated bone resorption due to a suppression of
osteoblastogenesis, and reduction in osteoclast apoptosis (Gilbert et al., 2000; Mundy, 2007). In
an OVX-induced osteoporosis mouse model, melatonin has been shown to reverse the bone loss
induced by an estrogen deficiency, which may be due to activation of the NLRP3 inflammasome
(Xu et al., 2018) via the Wnt/β-catenin pathway (Xu et al., 2018) and/or inhibition of NFκB
(Fernandez-Gil et al., 2017; Garcia et al., 2015; Korkmaz, Rosales-Corral, & Reiter, 2012; Z. Liu
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et al., 2017; Ortiz et al., 2015; Volt et al., 2016). Melatonin has also been shown to attenuate
inflammation-induced bone loss through other pathways that include: 1) suppression of activated
TLR4/NFκB signaling, 2) reduction in NFκB, TNF-α, and IL-1β levels (Mutoh, Tani-Ishii,
Tsukinoki, Chieda, & Watanabe, 2007), or 3) by regulating malondialdehyde (MDA) or
glutathione (GSH) (Kara et al., 2013). Melatonin’s in vivo effects are summarized in Table 4.
Table 4: Summary of melatonin’s actions on bone in in vivo models.
ANIMAL MODEL STUDIES
Endogenous/ Indirect Melatonin effect
References
Pinealectomy-induced Mel deficiency contributes to scoliosis in chicken (Machida et al.,
1995)
Different lighting conditions have an inducing effect upon the level of (Ostrowska,
Kosbiochemical markers of bone and mineral metabolism: distinct anomalies Kudla, Marek, et al.,
in daily oscillations of ALP, PICP, ICTP, HYP and calcium with a 2003)
negative correlation with endogenous Mel concentrations in rats
Pinealectomy induces, while exogenous Mel suppresses the level of bone (Ostrowska,
Kosmetabolism biomarkers (ALP, PICP, ICPT) in rats.
Kudla, Nowak, et al.,
2003)
Pinealectomized fish developed spinal malformations
(Fjelldal et al., 2004)
Mel has an osteoinductive effect on bone formation and absence due to (Turgut et al., 2005)
pinealectomy results in lower number of osteocyte, low BMD, and
scoliotic curvature in chicken
Pinealectomy induces bone loss reflected by decline in cancellous BV (Egermann et al.,
and thickness, increase in trabecular separation and bone resorption in 2011)
sheep
Pinealectomy leads to the development of scoliosis & osteoporosis maybe (Kono et al., 2011)
due to reduction of osteoblast proliferation and restoration of Mel
prevented this changes in chicken
Exogenous/ Direct Melatonin Effect
Animal Studies
References
Inhibition of bone resorption and increases bone mass in mice maybe (Koyama et al.,
through decreasing RANKL-mediated osteoclast formation and 2002)
activation.
Increases trabecular thickness, trabecular area, and cortical thickness in (Uslu et al., 2007)
rats without affecting osteoblast or osteoclast number
Increases OB activity and improves histomorphometry and (Sharan et al., 2017)
microarchitectural parameters on model of pineal gland‐specific deletion
of Tph1 through regulating OB function via MT2 receptor
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nocturnal supplementation increases bone density equal to estrogen–
progesterone HT and increases osteogenic markers (Runx2, Bmp2,
Bmp6, Bglap, and Per2) mRNA levels
Mel restores pinealectomy induced impairment of the bone repair process
in pinealectomized rats via restoration of connectivity density and
mineralization by exogenous melatonin administration
In old rat femora Mel decreases age-related bone loss in old rats and
increases bone volume, bone microarchitecture parameters and
biomechanical properties
Protects against LPS‐induced intra‐uterine fetal death and intra‐uterine
growth retardation probably via attenuation of LPS‐induced lipid
peroxidation in maternal liver in mice
Mel decreases OVX induced increase the number of apoptotic cells in
nucleus pulposus and epiphyseal cartilage in rats via inhibition of
inducible NO Synthase (iNOS) signaling in rats
Improves radiation induced damage of BMD and extrinsic properties of
the diaphyseal femur in rats
Changes in bone mass around prostheses in osteoporosis in presence of
oxidative stress in rats. This changes is accompanied by increase in ALP,
osteocalcin, and osterix expressions and periprosthetic bone mass &
implant fixation intensity, mitochondrial sirtuin 3 (SIRT3) expression and
decreases in the ratio of (AC-SOD2)/SOD2, NAPDH oxidase 2 &
cytochrome c expressions and restoration of osteogenesis potential.
Increases osteoblasts number and blood vessels as well as enhances new
mineralized tissue surfaces in diabetic rats via decreasing plasma levels
of Advanced Oxidation Protein Products, Malondialdehyde.
Alleviates OVX-induced bone loss, increases OB differentiation, serum
ALP and OCN and decreases TRAP in mice via suppressing NLRP3
inflammasome activation by regulating Wnt/β-catenin signaling
Inhibits wear debris-induced bone resorption, inflammatory cytokines
expressions, RANKL-induced OC differentiation and activity via
blocking of the IκB-α and p65 phosphorylation and inhibition of the
expression of NFATc1 and c-Fos.
Animal and in vitro model: Osteoblasts (OB) + Osteoclasts (OC)
Through MT2 receptors mediated pathway Mel induces osteoblast
differentiation and mineralization and inhibits osteoclastogenesis in
layered co-culture system by modulating ERK1/2, ERK5, β1 integrin,
GLUT4, and IRβ, ↑RUNX2, ↓PPARγ expressions and increasing
OPG:RANKL ratios.
Animal and in vitro model: Osteoblasts (OB)
Increases osteogenesis and decreases high glucose induced osteoblasts
autophagy in type 2 diabetic rats via inhibition of the ERK1/2 signaling
pathway (reduced p- ERK1/2 level)
In elderly rats increases BMD, bone formation rate, bone mineralization
rate, serum BAP and OCN, osteoblasts number, osteogenic
differentiation genes expressions and decreases adipocytes number,
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(P. A. Witt-Enderby
et al., 2012)
(Palin et al., 2018)
(Tresguerres et al.,
2014)
(Y. H. Chen et al.,
2006)
(Oktem et al., 2006)
(Cakir et al., 2016)
(W. Zhou et al.,
2019)

(Yildirimturk et al.,
2016)
(Xu et al., 2018)
(Ping et al., 2017)

References
(S. Maria et al.,
2018)

References
(W. L. Zhang et al.,
2016)
(Chu et al., 2017)

adipogenic differentiation genes expressions, urinary calcium, and
phosphorus losses
Restores postmenopausal osteoporosis (OP) by improving the osteogenic
differentiation of OP BMMSCs and ameliorating microarchitecture of
OVX rats and increasing matrix mineralization and osteoblast-specific
genes, SOD2, antioxidant and SIRT1
Animal and in vitro model: Osteoclasts (OC)
Increases BMD, decreases osteoclast surface, number, and activity
through downregulation of RANKL mRNA and OPG mRNA and protein
levels in mice.
Influence on callus formation and biomechanics during fracture healing
by suppressing bone resorption via decrease in RANKL-mediated
Osteoclast activation in mice.
Decreases bone resorption and inflammatory cytokines expressions,
osteoclast differentiation and activity via suppressing of NFκB signaling
in wear debris-induced osteolysis in rats
Maintains bone homeostasis, increases BMMSCs osteogenic action, but
suppresses of osteoclastogenesis via MT2‐inactivated NFκB pathway

(W. Chen et al.,
2020)
References
(Koyama et al.,
2002)
(Histing et al., 2012)
(Ping et al., 2017)
(Y. Zhou et al., 2020)

Mel- Melatonin, PICP- Procollagen I carboxyterminal propeptide, ICTP- Carboxyterminal
telopeptide of type I collagen, BMD-Bone mineral density, AIS- Adolescents with idiopathic
scoliosis, OC/OCN-Osteocalcin, CTX- N-terminal telopeptide, RANKL- receptor activator of
nuclear factor kappa B ligand, PPARγ- Peroxisome proliferator-activated receptor gamma,
GLUT4- Glucose transporter type 4, ALP- Alkaline phosphatase, HYP- Hydroxyproline, CaCalcium, OB-Osteoblast, Runx2- Runt-related transcription factor 2, Bmp2- Bone morphogenic
protein 2 , Bmp6- Bone morphogenic protein 6, Bglap- bone gamma-carboxyglutamic acidcontaining protein (osteocalcin), and Per2- Period Circadian Regulator 2, HT-Hormone therapy,
LPS-Lipopolysaccharide, iNOS- inducible NO Synthase, OVX- ovariectomized, NADPNicotinamide adenine dinucleotide phosphate, H2O2 - Hydrogen-peroxide, SIRT3- Sirtuin 3 ,
SOD2- Superoxide dismutase 2, AC-SOD2- Acetylated superoxide dismutase 2, TRAP-Tartrate
resistant acid phosphatase, NLRP3- NLR family pyrin domain containing 3, IkB-α- nuclear factor
of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha, NFATc1- Nuclear factor of
activated T-cells, cytoplasmic 1, hMSCs- Human mesenchymal stem cells, hPBMCs- Human
peripheral blood monocyte, OPG- osteoprotegerin, ERK1/2- Extracellular signal-regulated kinases
1/2, ERK5- Extracellular signal-regulated kinases 5, BMSC/ BMMSC- Bone marrow derived
mesenchymal stem cells, OPN- Osteopontin, ROS-Reactive oxygen species, MDAmalondialdehyde, MAPK- mitogen activated protein kinases, NFκB- nuclear factor kappa B.
As stated previously, melatonin works with or through myriad mechanisms to protect the bone that
includes the MAPK pathways, Wnt-beta catenin pathways, osteoblast-mediated inhibition of
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osteoclastogenesis through increases in OPG and RANKL decoy receptor actions, antioxidant, and
free radical scavenging properties (Table 4), making it an important molecule to study for
preventing or reversing bone loss. As osteopenia and osteoporosis are characterized by low bone
mass, formation and microarchitectural deterioration, the role of melatonin and MEK1/2 and 5 on
bone density and bone microarchitecture (chapter 4: histomorphometry and biomechanics) and
bone formation (chapter 5: new bone formation in calvarial defect assay) was studied using a small
molecule inhibitor approach (chapter 4) or a CRISPR/Cas9 knockout approach (chapter 5).
4.2. Approach and methodology
4.2.1 Treatment paradigm using Balb (c) mice and small molecule inhibitors
Balb(c) mice (29-32 day old) were maintained under a 12:12 light: dark (12L:12D) cycle. Within
one hour of lights off (~6pm), mice were injected (i.p.) daily with vehicle (DMSO; 0.01%),
melatonin (0.166mg/kg), Bix02189 (25mg/kg), MEK1/2 inhibitor (PD184352; 25mg/kg) and SC1-151 (25mg/kg) for 45 days. On day 45, mice were sacrificed, and their leg bones were harvested.
The right femur was snap frozen and used in the western blot analyses and the left femur was
cleared of muscle, wrapped in saline-soaked gauze, and subjected to microCT and mediolateral
three-point bending analyses (paradigm details in chapter 2). The experimental design is shown
in Figure 17.
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Figure 17: Experimental design and endpoints for in vivo small molecule inhibitor study
performed in Balb (c) mice.
4.2.1 Micro Computed Tomography (MicroCT) analysis on left femur
To assess the role of Mek1/2 or 5 in melatonin-mediated actions on bone density and
microarchitecture, Balb(c) mice, exposed to the treatments described above and in Figure 17, had
their femur bones subjected to microCT analysis to evaluate treatment effects on bone
morphometry. Specifically, treatment effects on trabecular bone microarchitecture and cortical
bone morphology were analyzed and parameters like bone volume fraction, trabecular thickness,
trabecular separation, number of trabeculae, structural model index, trabecular density, true
trabecular density, cortical area, cortical bone area fraction, cortical thickness, porosity, cortical
inner perimeter, cortical outer perimeter, polar moment of inertia, maximum moment of inertia,
and minimum moment of inertia were determined. Data were analyzed by two-way ANOVA to
determine if melatonin modulated bone density and microarchitecture and, if so, if melatonin
worked through Mek1/2 or Mek5 pathways . A schematic representation of this procedure is shown
in Figure 18.
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Figure 18: Histomorphometry-MicroCT analysis from in vivo small molecule inhibitor study
performed on left femur of Balb (c) mice.
4.2.1 Mediolateral three-point bending test on left femur
To determine treatment effects on bone strength, the same left femur from the microCT analysis
was then subjected to mediolateral three point bending test (method details in chapter 2) to study
treatment effects on bone biomechanics as described (Simkin & Robin, 1973). Specifically, a load
or force was applied to the mid diaphysis point of the left femur until broken (fracture)—this was
to generate a load vs displacement curve. The load vs displacement curve constructed was then
used along with other parameters (i.e., outer, and inner radius calculated from microCT and length
of the bone) to calculate the ultimate stress and modulus (Figure 19). Ultimate stress reflects the
bone’s capacity to withstand a load whereas the modulus provides information regarding the
bone’s rigidity.
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Figure 19: Biomechanical analysis-three-point bending test from in vivo small molecule
inhibitor study performed on left femur of Balb (c) mice.
4.2.1 Western blot analysis from right femur
To identify potential mechanisms of action and downstream mediators underlying melatonin’s
actions on bone, the right femur was used to prepare bone cell lysates, which was then subjected
to western blot analysis. Specifically, treatment effects on osteogenic protein expression (i.e.,
Runx2, Bmp-2, Fra-1, Type 1 collagen), osteoblast-osteoclast communication (i.e., Opg and
Rankl) and metabolic protein expression (i.e., Pparγ, Glut4, INRβ) were assessed (Figure 20).

Figure 20: Histomorphometry-protein analysis from in vivo small molecule inhibitor study
performed on right femur of Balb (c) mice.
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4.3. Results
4.3.1. The effect of melatonin, Mek1/2 or Mek5 inhibition on cortical bone morphology in
Balb(c) mice following 45 days of treatment
To characterize treatment effects on the degree of bone loss, full static histomorphometry assessing
the structural parameters of cortical bone was performed. No significant changes were observed
on any of the cortical bone morphology parameters analyzed (Figure 21A-L). These data are not
surprising considering that the treatments were for 45 days, and this treatment duration was
probably not long enough to see changes in cortical bone. This finding will inform future studies
with respect to treatment duration.
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Figure 21: Effects of melatonin and Mek1/2 and Mek5 inhibitors on different cortical bone
morphology parameters from in vivo small molecule inhibitor study performed in left femur of
Balb (c) mice. After 45 days of melatonin (0.166mg/kg) and inhibitor (PD184352, Bix02189, SC1-151) treatment, microCT analysis was performed to determine cortical bone morphology
parameters: (A) Polar moment of inertia, (B) Maximum moment of inertia, (C) Minimum moment
of inertia, (D) Bone area, (E) Tissue area, (F) Bone area/Tissue area, (G) cortical thickness, (H)
porosity, (I) Apparent density, (J) true density, (K) inner perimeter, and (L) outer perimeter of
mouse left femur. Left femur was scanned through a microCT scanner and cortical bone
morphology parameters were determined. Data were analyzed by two-way ANOVA followed by
Tukey Multiple Comparisons test. Each bar represents the mean (± SEM) value (n=4/5 per group
except for PD184352 treated groups, n=1/2). Significance was defined as p<0.05.
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4.3.2. The effect of melatonin, Mek1/2 or Mek5 inhibition on trabecular bone
microarchitecture (trabecular number, connectivity density and trabecular space) in Balb(c)
mice following 45 days of treatment.
To characterize changes in trabecular bone structure caused by melatonin and inhibitor treatment,
static morphometric analysis of trabecular bone using micro-CT scanning and 3D-reconstruction
on left femur was performed. When melatonin was administered in the presence of the Mek5
inhibitor, Bix02189 or the dual Mek1/2/5 inhibitor, SC-1-151, decreases in trabecular number
(number of trabeculae present per lineal mm ) (Figure 22A), decreases in connectivity density
(calculated by dividing the connectivity estimate of trabecular bone by the volume of the bone)
(Figure 22B), and increases in trabecular separation (local thickness of the marrow space in
between trabeculae) (Figure 22C) occurred. Significant inhibitory actions on the aforementioned
parameters occurred only in the presence of melatonin combined with Bix02189 (Mek5 inhibitor)
or SC-1-151 (dual Mek1/2 and 5 inhibitor) even through decreases (trends) occurred when Mek1/2
was inhibited using PD184352. These data lend support for a role of Mek5 and perhaps Mek1/2
in mediating melatonin’s actions on bone microarchitecture. Statistical analysis by two-way
ANOVA demonstrated an overall melatonin effect but no significant overall kinase effect and no
significant interaction between them further indicating role of these kinases in regulating bone
microarchitecture.
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Figure 22: Effects of melatonin and Mek1/2 and Mek5 inhibitors on trabecular number,
trabecular separation, and connectivity density from in vivo small molecule inhibitor study
performed in left femur of Balb (c) mice. After 45 days of melatonin (0.166mg/kg) and inhibitor
(PD184352, Bix02189, SC-1-151) treatment, microCT analysis was performed to determine
trabecular bone parameters: (A) trabecular number, (B) connectivity density, and (C) trabecular
separation from left femur. The left femur was scanned through a microCT scanner and trabecular
number, connectivity density, and trabecular separation were determined. Data were analyzed by
two-way ANOVA followed by tukey multiple comparison test and each bar represents the mean
(± SEM) value (n=4/5 per group except for PD184352 treated groups, n=1/2). Significance was
defined as p<0.05.

88

4.3.3. The effect of melatonin, Mek1/2 or Mek5 inhibition on trabecular bone
microarchitecture (trabecular density, structural model index, trabecular thickness, and
bone volume fraction) in Balb(c) mice following 45 days of treatment.
The actions of melatonin in the presence of the Mek1/2 or 5 inhibitors were specific to trabecular
number, connectivity density and spacing as no treatment effects were observed for: true trabecular
density (density of trabeculae), structural model index (change in surface curvature that occurs as
a structure of trabecular bone), trabecular thickness (thickness of trabeculae), and bone volume
fraction (bone volume/tissue volume) (Figure 23).
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Figure 23: Effects of melatonin and Mek1/2 and Mek5 inhibitors on true trabecular density,
structural model index, trabecular thickness, bone volume fraction from in vivo small molecule
inhibitor study performed in left femur of Balb (c) mice. After 45 days of melatonin (0.166mg/kg)
and inhibitor (PD184352, Bix02189, SC-1-151) treatment, microCT analysis was performed to
determine treatment effects on trabecular bone parameters: (A) true trabecular density, (B)
structural model index, (C) trabecular thickness, and (D) bone volume fraction of mouse left femur.
Following exposure to the treatments, the left femur bone was scanned through a microCT scanner
and true trabecular density, structural model index, trabecular thickness, and bone volume fraction
were determined. Data were analyzed by two-way ANOVA followed by Tukey Multiple
Comparisons test and each bar represents the mean (± SEM) value (n=4/5 per group except for
PD184352 treated groups, n=1/2). Significance was defined as p<0.05.
4.3.4. The effect of melatonin, Mek1/2 or Mek5 inhibition on breaking load (ultimate stress)
in Balb(c) mice following 45 days of treatment.
To characterize the effect of melatonin and role of Mek1/2 and Mek5 on “whole bone” as a
structure but, more specifically, the mechanical properties of the mid-diaphysis, mediolateral
three-point bending testing was performed. Biomechanical assessment revealed that the dual
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Mek1/2 and 5 inhibitor, SC-1-151 alone or combined with melatonin demonstrated decreases in
breaking load suggesting that the melatonin/SC-1-151-mediated decreases in trabecular number,
connectivity density, and increases in trabecular separation also resulted in decreases in bone
strength. Statistical analyses by two-way ANOVA revealed that for ultimate stress there was an
overall kinase effect and for modulus there was an overall melatonin effect even though no
significant treatment effects were observed. These data may suggest both Mek1/2 and Mek5
pathways underlie melatonin’s actions and are critical for maintaining its mechanical properties
but only when combined.

Figure 24: Effects of melatonin and Mek1/2 and Mek5 inhibitors on breaking load (ultimate
stress) and stiffness (modulus) from in vivo small molecule inhibitor study performed in left
femur of Balb (c) mice. After 45 days of melatonin (0.166mg/kg) and inhibitor (PD184352,
Bix02189, SC-1-151) treatment, three-point bending testing was performed to determine (A)
breaking load (ultimate stress), and (B) stiffness (modulus) of mouse femur bone. Load, applied
in the midpoint of the left femur until broken, allowed for the calculation of ultimate stress and
modulus. Data were analyzed by two-way ANOVA followed by Tukey Multiple Comparisons test
and each bar represents the mean (± SEM) value (n=4/5 per group except for PD184352 treated
groups, n=1/2). Significance was defined as p<0.05.
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4.3.5. The effect of melatonin, Mek1/2 or Mek5 inhibition on osteogenic (Runx2, Fra-1 and
Bmp-2) protein expression in Balb(c) mouse bone following 45 days of treatment.
To identify potential mechanisms underlying melatonin’s actions on bone microarchitecture
through Mek1/2 and Mek5, western blot analyses was performed on bone cell lysates prepared
from femur bone following the treatments. Specifically, melatonin exposure for 45 days in Balb(c)
mice increased levels of Runx2 (Figure 25A), Fra-1 (Figure 25B) and Bmp-2 (Figure 25C),
which was blocked in the presence of the Mek1/2 inhibitor (PD184352), Mek5 inhibitor
(Bix02189) or the dual Mek1/2 and 5 inhibitor (SC-1-151) (Figures 25A-C). Two-way ANOVA
analysis demonstrated overall melatonin effect on Runx2 and Fra-1 expression, an overall kinase
effect on Fra-1 and Bmp-2 expression and significant interactions between melatonin and the
kinases on Runx2 and Fra-1 expression occurred (Figure 25A-C), probably indicating the main
effect of both melatonin and kinases in Runx2 and Fra-1 expression and the main effect of kinases
in Bmp-2 expression. These data demonstrate that melatonin induces proteins involved in
osteogenesis in vivo and that these bone-enhancing effects were being mediated through Mek 1, 2
and 5. Mek5 inhibition by Bix02189 alone decreased Bmp-2 (Figure 25C). No treatment effects
were observed for type 1 collagen expression in bone (Figure D). Representative Runx2, Fra-1,
Bmp-2, and Type 1 collagen protein bands are also presented in Appendix 9.3.
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Figure 25: Effects of melatonin and Mek1/2 and Mek5 inhibitors on Runx2, Fra-1, Bmp-2, and
Type 1 collagen from in vivo small molecule inhibitor study performed in right femur of Balb
(c) mice. After 45 days of melatonin (0.166mg/kg) and inhibitor (PD184352, Bix02189, SC-1151) treatment, western blot was performed on bone cell lysates prepared from femur bone to
determine treatment effects on (A) Runx2 expression, (B) Fra-1 expression, (C) Bmp-2 expression,
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and (D) Type 1 collagen expression. In the representative protein bands, lanes do not represent
above treatment groups in specific order. Protein levels were normalized against β-actin. Data were
analyzed by two-way ANOVA followed by Tukey Multiple Comparisons test. Each bar represents
the mean (± SEM) expression of protein (n=4/5 per group). Significance was defined as p<0.05.
4.3.6. The effect of melatonin, Mek1/2 or Mek5 inhibition on osteoprotegerin, Rankl and
Nfκb protein expression in Balb(c) mouse bone following 45 days of treatment.
To identify potential mechanisms of action on melatonin’s actions on osteoclastogenesis, levels of
Opg, Rankl and Nfκb levels were measured by western blot following melatonin and inhibitor
(PD184352, Bix02189, SC-1-151) treatments (Figure 26A-D). A trend (p=0.06) was observed for
melatonin-mediated increases in osteoprotegerin (Opg) expression, which was no longer occurred
in the presence of the Mek5, Mek1 and Mek1/2/5 inhibitors (Figure 26A). Rankl levels remained
unchanged following exposure to melatonin treatment alone or in combination with the Mek5
inhibitor (Bix02189) or Mek1/2 inhibitor (PD184352). However, SC-1-151 alone or in presence
of melatonin, increased Rankl expression in bone (Figure 26B). Statistical analyses by two-way
ANOVA revealed a significant kinase effect for Rankl expression (Figure 26B). These findings
suggest that although melatonin is without effect on Rankl expression, when both Mek5 and Mek1
are simultaneously inhibited (by SC-1-151), then, and only then, is Rankl expression increased.
These findings parallel those effects observed for ultimate stress where melatonin combined with
SC-1-151 also decreased ultimate stress, suggesting that the melatonin/SC-1-151-induced
increases in Rankl may have contributed to the decreases in ultimate stress (or weakened bone)
through an increase in osteoclast activity and bone resorption. No significant treatment effects
were observed for ratios of Opg:Rankl (Figure 26C). Although no treatment effects occurred on
Nfκb levels in the presence of melatonin or PD184352 (Mek1/2 inhibitor), inhibition of Mek5 by
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Bix02189 decreased levels of Nfκb, suggesting the involvement of Mek5 in Nfκb expression and
potentially downstream signaling processes. Representative Opg, Rankl, and Nfκb protein bands
are also presented in Appendix 9.3.

Figure 26: Effects of melatonin and Mek1/2 and Mek5 inhibitors on Opg, Rankl, Opg/Rankl,
and Nfκb from in vivo small molecule inhibitor study performed in right femur of Balb (c) mice.
After 45 days of melatonin (0.166mg/kg) and inhibitor (PD184352, Bix02189, SC-1-151)
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treatment, western blot was performed on femur bone lysates to determine treatment effects on:
(A) Opg expression, (B) Rankl expression, (C) ratio of Opg/Rankl, and (D) Nfκb expression in
mouse right femur. In the representative protein bands, lanes do not represent above treatment
groups in specific order. Protein expression was normalized against β-actin. Data were analyzed
by two-way ANOVA followed by Tukey Multiple Comparisons test. Each bar represents the mean
(± SEM) expression of protein (n=4/5 per group). Significance was defined as p<0.05.

4.3.7. The effect of melatonin, Mek1/2 or Mek5 inhibition on metabolic (Pparγ Glut4, Insulin
receptor beta) protein expression in Balb(c) mouse bone following 45 days of treatment.
To identify potential mechanisms underlying melatonin’s actions on bone, the metabolic proteins,
Pparγ, Glut4 and Inrβ, were analyzed in mouse bone lysates following the treatments. Melatonin
decreased Pparγ expression, which was no longer observed after Mek1 or Mek5 or Mek1/2/5
inhibition. Two-way ANOVA revealed a significant kinase effect and melatonin effect in Pparγ
expression (Figure 27A), indicating the significant role of kinases and melatonin in regulating
Pparγ expression. Mek5 inhibition by Bix02189 alone decreased Pparγ and Glut4 suggesting that
Mek5 itself and other yet unknown signaling cascades are involved with their modulation (Figure
27B). No treatment effects were observed for Inrβ expression (Figure 27C). Representative Pparγ,
Glut4, and Inrβ protein bands are also shown in Appendix 9.3.
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Figure 27: Effects of melatonin and Mek1/2 and Mek5 inhibitors on Pparγ, Glut4, and Inrβ
from in vivo small molecule inhibitor study performed in right femur of Balb(c) mice. After 45
days of melatonin (0.166mg/kg) and inhibitor (PD184352, Bix02189, SC-1-151) treatment,
western blot analyses was performed on femur bone lysates to determine treatment effects on (A)
Pparγ expression, (B) Glut4 expression, and (C) Inrβ expression in mouse right femur. In the
representative protein bands, lanes do not represent above treatment groups in specific order.
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Protein expression was normalized against β-actin. Data were analyzed by two-way ANOVA
followed by tukey multiple comparison test and each bar represents the mean (± SEM) expression
of protein (n=4/5 per group). Significance was defined as p<0.05.
4.3.8. The effect of melatonin, Mek1/2 or Mek5 inhibition on beta-1 integrin protein
expression in Balb(c) mouse bone following 45 days of treatment.
Treatment effects on beta-1 integrin expression was assessed as integrins control different aspects
of bone cell growth and activity via regulating the interaction between bone cells and the
extracellular matrix (Mizuno, Fujisawa, & Kuboki, 2000). In our study, it was found that melatonin
was without effect on beta integrin and that blocking Mek1/2 and MEK5 separately or
simultaneously decreased beta-1 integrin expression irrespective of melatonin treatment indicating
the role of both pathways in beta-1 integrin expression (Figure 28). Representative beta-1 integrin
protein band is also shown in appendix 9.3.

Figure 28: Effects of melatonin and Mek1/2 and Mek5 inhibitors on beta 1 integrin from in
vivo small molecule inhibitor study performed in right femur of Balb(c) mice. After 45 days of
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melatonin (0.166mg/kg) and inhibitor (PD184352, Bix02189, SC-1-151) treatment, western blot
was performed on femur bone lysates to determine treatment effects on beta 1 integrin expression.
In the representative protein band, lanes do not represent above treatment groups in specific order.
Protein expression was normalized against β-actin. Data were analyzed by two-way ANOVA
followed by Tukey Multiple Comparisons test. Each bar represents the mean (± SEM) expression
of protein (n=4/5 per group). Significance was defined as p<0.05.
4.4. Discussion
Figure 29 summarizes all the findings from in vivo small molecule inhibitor study performed in
Balb (c) mice after treatment with melatonin and Mek1/2, Mek5, and Mek1/2/5 inhibitors. Similar
to MSCs, in vivo melatonin signaling in bone involves both MEK1/2 and MEK5 pathways.
Melatonin through Mek1/2 and Mek5 increased osteogenic protein Runx2, Fra-1, and Bmp-2
expression, decreased metabolic protein Pparγ and stimulate Opg release to regulate
osteoclastogenesis by osteoblasts. This is validated by the findings that when Mek1/2 was inhibited
by PD184352 and Mek5 was inhibited by Bix02189, melatonin’s effects were absent.
By regulating these proteins, melatonin through Mek1/2 and Mek5 might be regulating trabecular
bone microarchitecture and bone biomechanics as reflected by inhibitory effects on trabecular
number, connectivity density, trabecular separation, and bone breaking load (ultimate stress), when
there was simultaneous inhibition of Mek1/2 and Mek5 (through SC-1-151) in the presence of
melatonin.
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Figure 29: Summary of in vivo small molecule inhibitor study.

Although not studied specifically in the present work, MT2Rs have been demonstrated to play an
essential role in melatonin-mediated actions on bone using MT2R transgenic mouse model where
MT2Rs were knocked out (Sharan et al., 2017). Modulation of ERK1/2 (Radio et al., 2006) or
ERK5 (S. Maria et al., 2018) by melatonin through MT2Rs contributes to melatonin’s inducing
effect on osteoblastogenesis and inhibitory effect on osteoclastogenesis in MSCs in vitro. In this
study, the patterns of modulation of Runx2, Bmp-2, Fra-1, Pparγ, and Opg through the modulation
of Mek1/2 and Mek5 pathway in melatonin-exposed bone provide important mechanistic
information to explain the changes in bone microarchitecture and biomechanics observed in animal
bone and subsequently in human bone. Similar to what was observed in this study, the role of the
MAPK pathway in regulating Runx2 was also reported by Ge et al. (Ge et al., 2007; Ge et al.,
2009). The present study’s findings on Runx2 is important as this is considered as the master
regulator of osteogenesis and previous reports also demonstrated melatonin-mediated increases in
Runx2 in hMSCs (S. Maria et al., 2018; Sethi et al., 2010) and in bone (Koyama et al., 2002; P. A.
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Witt-Enderby et al., 2012). Another important pathway for osteogenesis, the Bmp-2 signaling
pathway, contributes to bone development and repair, specifically by increasing osteoblast
differentiation (G. Chen, Deng, & Li, 2012). Although the previous report shows induction of
Bmp-2 mRNA expression through MT2Rs after melatonin treatment (Sethi et al., 2010), the
present study confirms melatonin’s role in inducing Bmp-2 protein in bone. Transcription factor,
Fra-1 regulates bone mass through bone matrix production by osteoblasts (Eferl et al., 2004). In
this study, melatonin’s stimulatory effect on Fra-1 protein expression is first reported, which is
important in the study of bone as regulation of bone matrix can contribute to bone
histomorphometry and biomechanical properties (Sroga & Vashishth, 2012).
The in vivo inhibitor study further demonstrates that when both Mek5 and Mek1 are
simultaneously inhibited, then and only then, is Rankl expression increased and breaking load
(ultimate stress) of bone decreased. This finding may indicate that when it comes to bone
biomechanics, both pathways are equally important and Opg/Rankl ratio is a critical contributing
factor. This matches with our understanding of bone modeling and the bone remodeling process
as bone formation induced by osteoblasts inhibits osteoclastogenesis through the release of
osteoprotegerin (OPG), making OPG/RANKL ratio a critical marker for bone cell activity (S.
Maria et al., 2018; Maria S., 2014).
The effects of melatonin and Mek1 or Mek5 or Mek1/2/5 inhibition on metabolic proteins, PPARγ
and GLUT4, are important as they contribute to bone cell differentiation and activity (Akune et
al., 2004; Ferron et al., 2010; Z. Li et al., 2016; Takada, Suzawa, Matsumoto, & Kato, 2007). Maria
et al. reported that modulation of PPARγ through melatonin treatment might be the switch for
MSCs to move down osteogenesis rather than adipogenesis (S. Maria et al., 2018). Similar to the
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inhibitory effects of melatonin on PPARγ expression in hMSCs (S. Maria et al., 2018), inhibitory
effects of melatonin on Pparγ expression were also observed in the present study specifically in
bone. Moreover, in the present study, we further observed that inhibition of Mek5 itself inhibited
Pparγ expression, which is the first time reporting in bone, although it was reported in cancer cells
(Burgermeister & Seger, 2008). The fact that Mek1 or Mek5 inhibition modulated Pparγ
expression in mouse bone provides further mechanistic insight to explain the findings by Amstrup
et al. reporting improvements in bone density along with reductions in total fat mass and increases
in lean body mass in post- menopausal women with osteopenia after 1 year melatonin treatment
(Amstrup, Sikjaer, Heickendorff, et al., 2015; Amstrup et al., 2016).
Overall, melatonin regulates bone (trabecular bone microarchitectures, mechanical properties)
through modulating all the intracellular signaling molecules (proteins: Runx2, Bmp-2, Fra-1,
Pparγ, Opg) and this effect of melatonin on proteins related to melatonin mediated bone formation
is mostly similar to the finding of in vitro small molecule inhibitor study (S. Maria et al., 2018).
Moreover, Mek5 inhibition by Bix02189 alone decreased Pparγ and Glut 4, Bmp-2, Nfκb, and β1integrin expression indicating an involvement of other signaling pathways in their modulation,
which needs to be further studied through RNA Seq and lncRNA analyses.
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Chapter 5: Assessment of the role of MEK1/2 and 5 on melatonin-mediated action on bone
formation using calvarial defect assay and CRISPR/Cas9 approach.
5.1. Background
As stated previously, numerous studies have demonstrated that melatonin induces
osteoblastogenesis and increases BMD (Tables 1, 2 and 4) ; however, the mechanisms underlying
these actions in vivo are not clear even though in vitro studies argue strongly for a role of Mek1/2
and Mek5 in mediating these actions on osteoblastogenesis (Table 2: Role of melatonin in bone
remodeling: In vitro findings). Although Table 4 summarizes the findings from many in vivo
studies targeted to study bone mineral density, microarchitecture, and biomechanics, only a few
studies have examined melatonin’s effect on bone formation. A unique calvarial defect model was
developed in Balb (c) mice (male and female) utilizing a CRISPR/Cas9 knockout approach to
study the role of Mek1 or Mek5 in melatonin-mediated bone formation. These studies were
designed to (1) determine if the findings in vivo correlate to those found in vitro in mMSCs and in
hMSCs to further characterize mechanisms underlying these actions of melatonin and to translate
the findings to the human condition, respectively and (2) to determine if gender differences exist
between melatonin/Mek1- or Mek5-inducing actions on osteoblastogenesis .
5.2. Approach and methodology
Mek5KO and Mek1KO mMSCs were generated using the CRISPR/Cas9 knockout approach
(method details in chapter 2). Following confirmation that Mek1KO and Mek5KO occurred
(Figure 12 and 13), mMSCs (wildtype, control, Mek1KO and Mek5KO) were seeded onto poly
lactic-co-glycolic acid (PLGA) scaffolds and then placed into critical size calvarial defects
(method details in chapter 2). To maintain experimental continuity with the in vitro findings, the
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same mMSCs (wildtype, control, Mek1KO and Mek5KO) used in the in vitro studies (Chapter 3)
were also used in the calvarial defect studies. Figure 30 describes the experimental paradigm. In
brief, after mMSCs were seeded onto PLGA scaffolds and the scaffolds placed into each calvarial
defect created, mice (5 male and 5 female) were randomized to 6 scaffold groups: (1) untreated
control animals (containing no scaffold; vehicle or melatonin treatment), (2) PLGA scaffold only
(vehicle or melatonin treatment), (3) PLGA scaffolds seeded wildtype mMSCs (vehicle or
melatonin), (4) PLGA scaffolds seeded with control plasmid mMSCs (vehicle or melatonin), (5)
PLGA scaffolds seeded with Mek1KO mMSCs (vehicle or melatonin), and (6) PLGA scaffolds
seeded with Mek5KO mMSCs (vehicle or melatonin). Mice were then given melatonin (15mg/L)
or vehicle (0.1% ethanol) in their drinking water nightly for 90 days. Following the treatments,
mice were sacrificed, the skulls removed, and each sample was wrapped in 70% ethanol-soaked
gauze placed in a tightly sealed small container with some 70% ethanol to prevent the sample from
drying. Then they were sent to the Core Research Laboratory/Department of Pathology (University
of Alabama at Birmingham, AL) for static and dynamic analyses to assess new bone growth,
fibrous tissue growth, number of osteoblasts and osteoclasts, mineralized bone surface, bone
mineral apposition rate, and bone formation rate.
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Figure 30: Calvarial defect model development and endpoint analysis process in the center of
right parietal bone using knockout mMSCs in Balb (c) mice.
Static data analyses were performed using Goldner trichrome staining. In the Goldner trichrome
staining process, two or more acid dyes are used in conjunction with a polyacid to identify different
tissue types within bone by tinting them with contrasting colors (Rentsch et al., 2014). Figure 31
is a sample image of the defect after Goldner trichrome staining demonstrating different tissue
types highlighted in different colors where area with yellow border for pre-existing bone; green
for new bone; pink for fibrous tissue; red for osteoid; and orange for residual scaffold. Dynamic
data analyses was also performed on unstained slides in bone that was exposed to Calcein on days
80 and 87 of a 90-day treatment. The left and right-side boundaries were defined for each defect
(See large blue circle, 4mm diameter; Figure 31) to set the total defect area. The total defect area,
which included all tissues and their natural voids within the blue circle, was used to normalize data
generated for each tissue parameter analyzed. These values were then subjected to two-way
ANOVA (for gender-neutral analyses) and three-way ANOVA (for gender-specific analyses)
analysis.
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Figure 31: A sample picture of calvarial defect where different colors after trichrome staining
indicating different tissues.
5.3. Results
5.3.1. The effect of melatonin exposure on total tissue ingrowth in calvarial defects seeded
with mMSCs (wildtype, control, Mek1KO, Mek5KO).
Total tissue, which is the sum of pre-existing bone, osteoid, fibrous, new bone, and residual
scaffold was normalized by total defect area to calculate % total tissue in the defect zone and then
analyzed in total or stratified by gender. The percent total tissue in the defect zone was found to
be significantly higher in untreated controls (no scaffold) versus all other groups containing PLGA
scaffold (i.e., PLGA scaffold alone or PLGA scaffolds seeded with wildtype, control plasmid,
Mek1KO or Mek5KO mMSCs) when both males and females were combined (Figure 32A) or
stratified by gender (Figure 32B). Two-way ANOVA analysis demonstrated a significant
interaction between experimental condition (no scaffold vs scaffold containing different cells) and
melatonin (Figure 32A). When stratified by gender, three-way ANOVA analysis revealed a
significant interaction by treatment condition (no scaffold vs scaffold containing different cells)
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(Figure 32B). Overall, these findings demonstrate that the PLGA scaffold inhibited total tissue
ingrowth into the defect zone.

Figure 32: Role of Mek1 and Mek5 on melatonin’s effect on % total (Tt.) tissue in defect zone
using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA
scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were
created in Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin
(15mg/L given nightly in drinking water).

Following the treatment, calvarial defects were

removed and subjected to static analysis using Goldner trichrome staining to quantify total tissue
area (pre-existing bone + osteoid + fibrous+ new bone + residual scaffold). Total tissue area was
then normalized by total defect area and subjected to statistical analysis. (A) Two-way ANOVA
was conducted on tissues that combined both males and females (gender-neutral analysis) or (B)
three-way ANOVA was conducted on tissues when stratified by gender. In the gender-neutral
analyses, each bar represents the mean (± SEM) with an “n” of 6-10 and in gender-specific
analysis, each bar represents the mean (± SEM) with an “n” of 3-5. Significance was defined as
p<0.05.
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5.3.2. The effect of melatonin exposure on percent new bone in calvarial defects seeded with
mMSCs (wildtype, control, Mek1KO, Mek5KO).
Gender-neutral analysis (i.e., male, and female tissues combined) demonstrated that percent new
bone in total tissue was significantly higher in in all PLGA scaffold-containing specimens (with
or without mMSCs) versus untreated controls (no scaffold) irrespective of melatonin treatment.
Melatonin treatment further increased percent new bone in total tissue in wildtype and control
plasmid mMSCs groups (Figure 33A). In Figure 33A, two-way ANOVA in gender-neutral
analysis revealed a significant kinase effect and a melatonin effect (trends; p=0.06). These findings
suggest that melatonin and Mek1 or Mek5 played a significant role supporting the hypothesis that
melatonin increases percent new bone through Mek1 and Mek5, consistent with what was
demonstrated in vitro. When the tissues were stratified by gender, trends for melatonin-mediated
increases in percent new bone occurred for wildtype cells [male (p=0.08) and female (p=0.09)] ,
control plasmid cells (female only; p= 0.09), and Mek1KO cells (female only; p= 0.08) (Figure
33B). Three-way ANOVA revealed significant interactions by treatment, or by melatonin or by
gender (Figure 33B). These data demonstrate that the melatonin-mediated increases in percent
new bone in female mice are being modulating through Mek5, but in male mice it may be through
both Mek1 and Mek5. Considering that the mMSCs used in the calvarial defect analyses were
derived from female mice but when seeded on the PLGA scaffolds and placed in male or female
mice indicates that hormonal influences (estrogen, progesterone, and testosterone) are playing a
significant role in these melatonin-mediated increases in new bone formation.
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Figure 33: Role of Mek1 and Mek5 on melatonin’s effect on % new bone in total tissue area
using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA
scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were
created in Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin
(15mg/L given nightly in drinking water).

Following the treatment, calvarial defects were

removed and subjected to static analysis using Goldner trichrome staining to quantify % new bone
formation. New bone area, normalized by total tissue area, was subjected to statistical analysis—
two-way ANOVA for gender-neutral analyses (males and females combined) (A), and three-way
ANOVA when stratified by gender (B). In the gender-neutral analyses, each bar represents the
mean (± SEM) with an “n” of 6-10 and in the gender-specific analysis, each bar represents the
mean (± SEM) with an “n” of 3-5. Significance was defined as p<0.05.
5.3.3. The effect of melatonin exposure on fibrous tissue formation in calvarial defects seeded
with mMSCs (wildtype, control, Mek1KO, Mek5KO).
The ingrowth of fibrous tissue could impede new bone formation and so decreases in fibrous tissue
formation would be beneficial to new bone formation (Rotman, Hamdy, & Appelman-Dijkstra,
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2019). Gender-neutral analysis demonstrates that when Mek5 or Mek1 (trends) was removed in
mMSCs, melatonin significantly decreased percent fibrous tissue in total tissue (Figure 34A),
which remained in male calvarial defects seeded with Mek1KO mMSCs (Figure 34B). These
findings suggest that Mek5 and perhaps Mek1 modulate fibrous tissue growth. Furthermore, the
gender-specific analyses demonstrate that melatonin’s inhibitory effect on fibrous tissue formation
in calvarial defects seeded with Mek5KO mMSCs observed in male mice but not in female mice
(Figure 34B). These findings indicate that hormonal (i.e., estrogen, progesterone, testosterone)
influences are playing a pivotal role in fibrous tissue formation and suggests that melatonin may
be acting via Mek5 to influence fibrous tissue formation more in males than in females.
Furthermore, these findings also signal towards treatment condition’s influence on immune
reaction regulating fibrous tissue formation.

Figure 34: Role of Mek1 and Mek5 on melatonin’s effect on % fibrous tissue in total tissue
using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA
scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were
created in Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin
(15mg/L given nightly in drinking water).

Following the treatment, calvarial defects were
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removed and subjected to static analysis using Goldner trichrome staining to quantify fibrous tissue
formation. Fibrous tissue area, normalized by total tissue area, was subjected to statistical
analyses—two-way ANOVA for the gender-neutral analysis (A) and three-way ANOVA for
gender-specific analyses (B). For the gender-neutral analyses, each bar represents the mean (±
SEM) with an “n” of 6-10 and for the gender-specific analyses, each bar represents the mean (±
SEM) with an “n” of 3-5. Significance was defined as p<0.05.
5.3.4. The effect of melatonin exposure on PLGA scaffold tolerance in calvarial defects
seeded with mMSCs (wildtype, control, Mek1KO, Mek5KO).
Gender-neutral (Figure 35A) and gender-specific (Figure 35B) analysis demonstrates almost total
loss of the scaffold and no significant difference among all groups for percent residual scaffold
suggesting that the scaffold was tolerated and able to disintegrate, which is critical to healthy new
bone formation (Clafshenkel et al., 2012).

Figure 35: Role of Mek1 and Mek5 on melatonin’s effect on % residual scaffold in total tissue
using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA
scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were

111

created in Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin
(15mg/L given nightly in drinking water).

Following the treatment, calvarial defects were

removed and subjected to static analysis using Goldner trichrome staining to quantify residual
scaffold. Residual scaffold area, normalized by total tissue area, was subjected to statistical
analyses—two-way ANOVA for gender-neutral analysis (A) and three-way ANOVA for the
gender-specific analysis (B). For the gender-neutral analysis, each bar represents the mean (±
SEM) with an “n” of 6-10 and for the gender-specific analysis, each bar represents the mean (±
SEM) with an “n” of 3-5. Significance was defined as p<0.05.
5.3.5. The effect of melatonin exposure on osteoblast proliferation in calvarial defects seeded
with mMSCs (wildtype, control, Mek1KO, Mek5KO).
Similar to the inhibitory effects of PLGA scaffolds on total tissue ingrowth versus no PLGA
scaffold groups, treatment effects on osteoblast number, gender-neutral analysis (males and
females combined) demonstrated that in untreated controls (no PLGA scaffold), total osteoblast
number was significantly higher compared to all other groups (i.e., PLGA scaffold only or PLGA
scaffold seeded with wildtype, control plasmid, Mek1KO, Mek5KO mMSCs) irrespective of
melatonin treatment (Figure 36A). Also, gender-neutral and gender-specific statistical analyses
demonstrate that melatonin was without effect on osteoblast number (Figure 36A and 36B). These
data suggest that melatonin, under these experimental conditions, does not induce
osteoblastogenesis. This is surprising considering that past studies (K. H. Park et al., 2011) using
mMSCs demonstrated that melatonin induces osteoblastogenesis (Figure 14 and Table 2). What
may account for these discrepancies between the in vitro and in vivo studies on melatonin effects
on osteoblast numbers could be in the analyses of the calvarial defects. Osteoblasts were identified
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morphologically using Bioquant. The fact that fibroblasts have similar morphological features as
osteoblasts may have resulted in fibroblasts being counted in as osteoblasts skewing the data
making it difficult to draw any conclusions from this analyses.

Figure 36: Role of Mek1 and Mek5 on melatonin’s effect on number of osteoblast per area
using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA
scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were
created in Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin
(15mg/L given nightly in drinking water). Following the treatment, calvarial defects were removed
and subjected to static analysis using Goldner trichrome staining to quantify total osteoblast
numbers. Total number of osteoblasts, normalized by total area of random view at 20X, were
subjected to statistical analyses—two-way ANOVA for gender-neutral analysis (A) and three-way
ANOVA for gender-specific analysis (B). For the gender-neutral analysis, each bar represents the
mean (± SEM) with an “n” of 6-10 and for the gender-specific analysis, each bar represents the
mean (± SEM) with an “n” of 3-5. Significance was defined as p<0.05.
5.3.6. The effect of melatonin exposure on osteoclast proliferation in calvarial defects seeded
with mMSCs (wildtype, control, Mek1KO, Mek5KO).
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Gender-neutral analysis shows that total osteoclast number was significantly higher in calvarial
defects containing PLGA scaffolds (PLGA only or PLGA scaffolds seeded with wildtype, control
plasmid, Mek1KO or Mek5KO mMSCs) versus untreated controls irrespective of the treatments
(vehicle or melatonin) (Figure 37A). From the gender-specific analysis, it was found that
melatonin treatment decreased (p=0.08) osteoclast number in female mice with calvarial defects
seeded with wildtype mMSCs compared to vehicle (Figure 37B). In all other groups, including
control plasmid, this inhibitory effect of melatonin on osteoclast number was lost.

Figure 37: Role of Mek1 and Mek5 on melatonin’s effect on osteoclast number using calvarial
defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA scaffold or
PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were created in
Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin (15mg/L given
nightly in drinking water). Following the treatment, calvarial defects were removed and subjected
to static analysis using Goldner trichrome staining and TRAP staining to quantify total number of
osteoclasts. Total number of osteoclasts, normalized by total tissue area, were subjected to
statistical analyses—two-way ANOVA for gender-neutral analysis (A) and three-way ANOVA
for gender-specific analysis (B). For the gender-neutral analysis, each bar represents the mean (±
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SEM) with an “n” of 6-10 and for the gender-specific analysis, each bar represents the mean (±
SEM) with an “n” of 3-5. Significance was defined as p<0.05.

5.3.7. The effect of melatonin exposure on mineralized bone in calvarial defects seeded with
mMSCs (wildtype, control, Mek1KO, Mek5KO).
Gender-neutral (Figure 38A) and gender-specific (Figure 38B) analyses demonstrate that
melatonin-mediated increases in percent mineralized bone surface per bone surface (MS/BS)
occurred in the untreated control group (Figure 38A) and in female mice containing no scaffold
(Figure 38B). No other treatment effects were observed. These findings suggest that melatonin
may be increasing bone mineralization in general in female mice possibly due to a hormonal
(estrogen, progesterone) effect supported by the three-way ANOVA demonstrating a significant
interaction between melatonin and gender (Figure 38B).

Figure 38: Role of Mek1 and Mek5 on melatonin’s effect on % of mineralized surface per bone
surface using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing
no PLGA scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO
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mMSCs were created in Balb(c) mice (male and female) and subjected to a 90-day exposure to
melatonin (15mg/L given nightly in drinking water). Following the treatment, calvarial defects
were removed and subjected to dynamic analysis on unstained slides to quantify mineralized bone
surface (MS). Mineralized surface area, normalized by total bone surface area, was subjected to
statistical analyses—two-way ANOVA for gender-neutral analysis (A) and three-way ANOVA
for gender-specific analysis (B). For the gender-neutral analysis, each bar represents the mean (±
SEM) with an “n” of 6-10 and for the gender-specific analysis, each bar represents the mean (±
SEM) with an “n” of 3-5. Significance was defined as p<0.05.

5.3.8. The effect of melatonin exposure on mineral apposition in calvarial defects seeded with
mMSCs (wildtype, control, Mek1KO, Mek5KO).
As shown in Figure 39, the mineral apposition rate (MAR), a marker of bone formation, is
calculated using the distance between the midpoints or between the corresponding edges of two
consecutive Calcein labels, divided by the time between the midpoints of the labeling periods
(Schilling, Mueller, Minne, & Ziegler, 1992).

Figure 39: Calcein injection showing fluorescence indicating new bone formation.
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Gender-neutral analysis shows that the mineral apposition rate was significantly higher in calvarial
defects containing PLGA scaffolds (PLGA scaffold only and PLGA scaffolds seeded with
wildtype, control plasmid, Mek1KO, and Mek5KO mMSCs). No other treatment effects were
observed (Figure 40A).When stratified by gender, the data demonstrate that the apposition rate
was higher in all male mice with defects containing PLGA scaffolds (except for Mek1KO group)
compared to untreated controls (Figure 40B). These data demonstrate that gender and most likely
hormonal influences (estrogen, progesterone, testosterone) are playing a role in the mineral
apposition process in males and perhaps through Mek1.

Figure 40: Role of Mek1 and Mek5 on melatonin’s effect on mineral apposition rate using
calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects containing no PLGA
scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or Mek5KO mMSCs were
created in Balb(c) mice (male and female) and subjected to a 90-day exposure to melatonin
(15mg/L given nightly in drinking water).

Following the treatment, calvarial defects were

removed and subjected to dynamic analyses on unstained slides to quantify mineral apposition
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rate . Mineral apposition rate (MAR) was calculated by quantifying the distance between the
midpoints of two consecutive Calcein labels (injected on day 80 and 87), divided by the time
between the midpoints of the labeling periods. Quantified mineralized surface area was then
subjected to statistical analyses—two-way ANOVA for gender-neutral analysis (A) and three-way
ANOVA for the gender-specific analysis (B). For the gender-neutral analysis, each bar represents
the mean (± SEM) with an “n” of 6-10 and for the gender-specific analysis, each bar represents
the mean (± SEM) with an “n” of 3-5. Significance was defined as p<0.05.
5.3.9. The effect of melatonin exposure on bone formation rate in calvarial defects seeded
with mMSCs (wildtype, control, Mek1KO, Mek5KO).
The role of melatonin, Mek1 and Mek5 on bone formation rate was assessed. Gender-neutral
analysis demonstrates that melatonin increased bone formation rate compared to vehicle in the
untreated control group (no PLGA scaffold) (Figure 41A). Gender-specific analysis (Figure 41B)
demonstrates that melatonin still increased bone formation rate (bone formation rate per bone
surface per day) in both male and female untreated control (no scaffold) groups. When stratified
by gender, melatonin produced a decrease in bone formation rate in male mice with wildtype
mMSCs seeded on PLGA scaffolds. In control cells (control mMSCs), melatonin was without
effect in males and trends (p=0.07) towards an increase occurred in females. No melatonin effect
was observed in Mek1KO or Mek5KO mice suggesting that Mek1 and Mek5 are involved in
melatonin-induced increase in bone formation rate in females. Statistical analysis by three-way
ANOVA reveals an overall significant melatonin effect, gender effect, and a significant interaction
between melatonin and gender (Figure 41B). These findings support a role for hormonal
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influences (i.e., estrogen and progesterone) on modulating melatonin-mediated increases in bone
formation.

Figure 41: Role of Mek1 and Mek5 on melatonin’s effect on bone formation rate per bone
surface per day using calvarial defect assay and CRISPR/Cas9 approach. Calvarial defects
containing no PLGA scaffold or PLGA scaffolds seeded with wildtype, control, Mek1KO or
Mek5KO mMSCs were created in Balb(c) mice (male and female) and subjected to a 90-day
exposure to melatonin (15mg/L given nightly in drinking water). Following the treatment, calvarial
defects were removed and subjected to dynamic analyses on unstained slides to quantify bone
formation rate. Mineralized surface area, first normalized by total bone surface area and then
normalized by total treatment days, was subjected to statistical analyses—two-way ANOVA for
gender-neutral analysis (A) and three-way ANOVA for gender-specific analysis (B). For the
gender-neutral analysis, each bar represents the mean (± SEM) with an “n” of 6-10 and for the
gender-specific analysis, each bar represents the mean (± SEM) with an “n” of 3-5. Significance
was defined as p<0.05.
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5.4. Discussion
Melatonin increased new bone formation in both wildtype and control plasmid cells containing
scaffold and both Mek1 and Mek5 deficiencies blocked melatonin’s effect indicating the role of
both the kinases in the gender-neutral analysis. Gender differences were noted in melatonin’s
effect between males and females and in the case of kinase interaction with melatonin. The fact
that female mMSCs were used in both groups and yet gender differences were observed suggest
that hormonal influences may be occurring; this is possible considering that the mice during these
experiments were 29-32 days (~1 month old) at the outset of the study and 120 days (~4 months
old) at the end signifying that they were sexually mature (Dutta & Sengupta, 2016) and secreting
estrogen, progesterone, and testosterone. Table 5 describes the comparisons between the in vitro
and in vivo studies using mMSCs or in Balb(c). Briefly, melatonin induced osteoblastogenesis in
mMSCs and, similarly, induced Runx2 expression and new bone formation in vivo. These
melatonin-mediated actions were blocked when Mek1/2 or Mek5 either via pharmacological
inhibition or knockout was inhibited or knocked out, respectively. Differences (noted in orange;
Table 5) between mMSCs and bone were observed in case of Mek1/2 or Mek5 inhibition alone
(i.e., no melatonin), where inhibition of Mek1/2 or 5 by small molecule inhibitors or knock out
decreased osteoblastogenesis in mMSCs and was without effect in bone. This difference could be
due to the fact that the in vivo environment has greater interplay between physiological systems
and factors that would not be picked up in a simpler mMSC monoculture model.
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Table 5: Overall summary table comparing mouse cell to mouse in vivo study
Parameters

Osteoblastogenesis, new bone or Runx2
(Compared to vehicle)
Mouse (monoculture):
Osteoblastogenesis

Mouse ( in vivo):
New bone or RUNX2

Melatonin’s effect

Increased

Increased

Mek1/2 inhibitor

Decreased

No effect

Mek1/2 inhibitor + Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

Mek1/2 Knockout

Decreased

No effect

Mek1/2 Knockout + Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

MEK5 or Mek5 inhibitor

Decreased

No effect

MEK5 or Mek5 inhibitor+ Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

Mek5 Knockout

Decreased

No effect

Mek5 Knockout+ Melatonin

Blocked Mel’s effect

Blocked Mel’s effect

Melatonin’s effect on increasing new bone formation but not osteoblast number in calvarial defects
can be explained through recent reports demonstrating melatonin-mediated increases in bone mass
accrual around prosthesis via an increase in osterix (an osteogenic protein ) expression (W. Zhou
et al., 2019), which is increased in mature osteoblasts to increase bone matrix mineralization
(Zoch, Clemens, & Riddle, 2016). Da et al. reported melatonin-mediated increases in matrix
mineralization by enhancing citrate secretion into the bone matrix (Da et al., 2020). These studies
help to explain further melatonin’s role in new bone formation (i.e., through bone matrix
mineralization processes) especially the results demonstrated in the MelaOst clinical trial reporting
an increase in BMD in response to a one-year melatonin (1, 3mg) that was not associated with
increases in P1NP or CTx but was associated with decreases in urinary calcium excretion
(Amstrup, Sikjaer, Heickendorff, et al., 2015).
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The mechanisms underlying these melatonin-mediated increases in bone mineralization may be
through Runx2, the master transcriptional regulator of bone, which is expressed in both mouse and
human osteoprogenitor cells (C. K. Chan et al., 2015; C. K. F. Chan et al., 2018). This idea is
supported in studies where germline deletion of Runx2 causes complete absence of mineralized
bone in both mouse calvaria and long bones (Takarada et al., 2016). The fact that melatoninmediated increases in Runx2 expression and bone formation occurred despite no increases in
osteoblast number may, perhaps, be explained by Runx2 working through mineralization processes
potentially through Mek1 and Mek5. This idea is supported by the findings in past and present
findings that (1) both Mek1 and Mek5 pathways play significant roles in modulating melatonin’s
action on Runx2 expression in hMSCs (Maria et al., 2018) and in bone (present study) indicating
that both pathways are critical for melatonin-mediated actions on bone mineralization; (2) that
constitutively active Mek1 in osteoprogenitor cells contributes to increased bone strength but
impairs mineralization in a manner leading to irregular bone geometry (Fowlkes et al., 2020); and
(3) that the MEK5/ERK5 pathway was found to not only influence osteoblast differentiation but
also bone mineralization (Adam et al., 2018). Perhaps Mek1 or Mek5 in osteoprogenitor cells was
contributing to the overactivation of Runx2, leading to increased bone mineralization. This idea
needs to be expanded upon in future studies.

122

Chapter 6: Strengths and Limitations
Strengths
Various in vitro and in vivo approaches thoroughly examined the project hypothesis to identify the
role of MEK1/2 and MEK5 on regulating melatonin-mediated osteoblast and osteoclast
differentiation, function, and bone formation. The in vitro approach was further improved by the
use of

human cell lines, which increased the translatability of the findings. Moreover,

experimental conditions were developed utilizing both osteoclasts and osteoblasts to mimic the
bone microenvironment to correlate with the in vivo findings. This unique transwell co-culture
model system allows assessment of the activities of both osteoblasts and osteoclasts by measuring
mineral deposition by osteoblasts and resorption pit formation on bone chips by osteoclasts,
respectively. The highly specific CRISPR/Cas9 knockout approach was utilized to understand
MEK1 and MEK5’s role in melatonin-mediated actions in osteoblastogenesis, bone density,
microarchitecture, biomechanics and formation coupled with small molecule inhibitors as some
small molecule inhibitors may not be as selective as touted. Moreover, both approaches were even
simultaneously studied in the same experimental settings in vitro in mouse MSC monocultures. A
successful CRISPR/Cas9 transfection protocol was developed for use in hMSCs and mMSCs,
which allowed for the creation of MEK1 or MEK5 knockouts in hMSCs or mMSCs. This is
important as MSCs are multipotent stem cells and sensitive towards drastic approaches. The
creation of MEK1 or MEK5 knockouts in mMSCs and hMSCs and this protocol in general can be
used for future research involving MSCs. With the aid of these highly sophisticated and precisely
design methodologies, new critical information has been added to the field of bone and melatonin
research. The similarity of melatonin’s mechanism on osteoblastogenesis through MT2Rs, MEK1
and MEK5 in both human and mouse MSCs was first reported in this project. New downstream

123

targets (i.e., FRA-1) of MEK5 and MEK1 were identified as potential mediators of melatoninmediated osteoblastogenesis. The gender differences observed regarding melatonin’s interaction
with kinases were noted for the first time. The last finding is important as it will potentially lead
to the development of customized and effective therapies targeted to the unique needs of males
and females with osteopenia or osteoporosis.

Limitations
Some limitations of the study include technical limitations of some assays especially in controlling
RANKL and M-CSF diffusion between chambers, which may impact on the final concentration of
these molecules. The communication between chambers was a critical component of the project
in order to answer melatonin’s role in osteoblast-mediated actions on osteoclastogenesis. Another
limitation was using small molecule inhibitors to study the role of MEK1/2 or MEK5 in melatoninmediated actions on osteoblast and osteoclast differentiation and bone density, microarchitecture
and biomechanics due to the potential for non-selective actions as reported (Drew et al., 2012).
This issue was circumvented by using the CRISPR/Cas9 knockout approach. Also, there are some
underlying differences between rodent and human bone development (Jilka, 2013), and it may
have contributed to some differences in data. It was also determined that 45 days of treatment was
not sufficient to ascertain treatment effects on cortical bone parameters. However, this information
was used in the design of the calvarial defect treatment duration, which was set to 90 days.
Although no study exists demonstrating the involvement of Mek1/2 or Mek5 in modulating
melatonin rhythms, there is a chance of a potential inhibitor effect on disrupting endogenous
melatonin levels. However, this may not have been as dramatic of an issue because Balb(c) mice
have a unique melatonin rhythm that is short in duration allowing for studies assessing the impact
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of exogenous melatonin administration on bone cell/bone parameters. The western blot analysis
using bone lysates does not allow us to decipher which cells are expressing Bmp-2 or Runx-2 in
the bone microenvironment, although our in vitro work published previously establishes that these
actions of melatonin are primarily through the osteoblast (S. Maria et al., 2018).
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Chapter 7: Conclusions and future directions
This study successfully added critical new information regarding the mechanisms underlying
melatonin-mediated actions on bone providing fodder for further research in bone-, melatonin- and
metabolism-related research fields. The similarity between human and mouse MSCs in terms of
melatonin’s effect on osteoblastogenesis occurring strictly through MT2R-mediated actions on
MEK5 and/or MEK1 and not through an indirect action was important as melatonin has been
demonstrated to produce receptor-independent actions. The importance of both the Mek1/2 and
Mek5 pathways in regulating trabecular bone microarchitecture parameters (trabecular number,
connectivity density, and trabecular separation), bone biomechanics (ultimate stress) and Rankl is
opening new windows for further research to study the connection between these critical bone
parameters. Mek5 inhibition by Bix02189 alone in bone decreasing Pparγ,Glut4, Bmp-2, Nfκb,
and β1-integrin expression suggests that Mek5 itself and other yet unknown signaling cascades are
involved with their modulation. Future research using RNA Seq and lncRNA analyses may help
us identify these pathways. Finally, the gender differences reported regarding melatonin’s actions
in new bone formation is very important in understanding bone loss as the morphologic pattern of
osteocalcin distribution in the bone matrix changes with age and gender, which may be
responsible, in part, for the altered bone remodeling associated with gender and aging (Ingram,
Park, Clarke, & Fitzpatrick, 1994).

The melatonin signaling that occurs during osteoblastogenesis and osteoclastogenesis is becoming
clearer and demonstrates the complexity of interaction between differentiating osteoblasts from
MSCs and differentiating osteoclasts from osteoclastic precursor cells and the role that the
MAPKs, MEK1/2 and 5, play in this process (See Figure 42).
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Figure 42: Overall conclusion of melatonin signaling and melatonin’s effects in vitro and in
vivo. Melatonin, in human MSCs and mMSCs (both in vitro and in vivo) modulates
osteoblastogenesis via MT2 melatonin receptor by activating both MEK1/2 and MEK5 pathway.
MEK5 activation results in increases in pERK5, RUNX2, NFκB, GLUT4, BMP-2, and FRA-1.
Activation of MEK1/2 leads to increases in pERK1/2, RUNX2, BMP-2, and FRA-1 and decreases
in PPARγ, GLUT4, and IRβ. In combination these two pathways determine the fate of MSCs
moving it away from adipogenesis and toward osteogenesis. Following MSC differentiation into
osteoblasts by melatonin, the mature osteoblasts through OPG secretion can inhibit
osteoclastogenesis from osteoclast precursor. The melatonin signaling that is happening in MSCs
and OCP contributes to the melatonin’s effect observed in vitro and in vivo. In both monocultures
of hMSCs and mMSCs and co-culture of MSCs-OCP, melatonin might be working through MEK1
and MEK5 to induce osteoblastogenesis, which inhibited osteoclastogenesis in the upper chamber
of the co-culture. In vivo melatonin’s observed effect can be stratified in two categories: bone
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formation in calvarial defect assay and bone metabolism through histomorphometry and
biomechanical analysis. Melatonin through Mek1 and Mek5 increased new bone formation along
with an increase in mineralized bone surface and a decrease in osteoclast number. Melatonin,
through Mek5 and maybe Mek1/2 pathways modulated trabecular bone microarchitecture, which
was reflected by changes in bone biomechanics.

These mechanisms of action of the MAPKs, MEK1/2 and 5, coupled with their unique
actions on osteogenic pathways (mainly MEK5 effect) and metabolic protein pathways (mainly
MEK1/2 effect) opens up new avenues of research examining conditions known to promote bone
loss that include metabolic conditions like diabetes, lifestyle conditions like poor sleep, poor eating
as well as aging. These factors need to be further studied and factored into therapies targeted to
prevent or treat bone-related conditions.
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Chapter 9: Appendices
9.1. Full blot and MEK1 band images for hMSCs

Figure 43:Confirmation of MEK1KO and ME51KO in hMSCs.
(A) Full blot total protein and MEK1 band images in western blot analysis where different lanes
representing different groups. (B) Full blot total protein and MEK5 band images in western blot
analysis where different lanes representing different groups.
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9.2. Three-way ANOVA performed on ALZ, TRAP, and Resorption pit formation assay in
hMSCs-hOCP co-culture.

Figure 44:Effect of melatonin and role of MEK1 and MEK5 on osteoblast mediated calcium
deposition and osteoclast-mediated TRAP enzyme release and resorption pit formation in
hMSCs-hOCP transwell coculture.
(A) Following 21 days of exposure to vehicle or melatonin treatments, calcium deposition by
differentiated, matured osteoblasts was evaluated by alizarin red staining in simple monoculture
model. Each bar represents the mean OD value (± SEM) reflecting concentration of alizarin red
for the respective group normalized against Os+_Wildtype_Vehicle. Data were analyzed by threeway ANOVA followed by tukey multiple comparison test (n=3 per group). On day 21, 9 days after
osteoclast precursor plating, TRAP enzyme release and resorption pit formation by the

151

differentiated osteoclasts in the upper chamber of transwell and on bone chips were measured via
quantitative TRAP staining and resorption pit formation assay, respectively. Data were analyzed
to determine (B) TRAP expression by differentiated osteoclasts in different groups, and (C)
Resorption pit formation activity in different groups by mature osteoclasts. Each bar represents the
mean (± SEM) fluorescence reading of TRAP (absolute value at 405 nm ex, 515 nm em) or area
of resorption pit for respective groups normalized against Os-_Wildtype_Vehicle for respective
groups. Data were analyzed by three-way ANOVA followed by tukey multiple comparison test
(n=3 per group). Significance was defined as p<0.05.
9.3. Protein band images of in vivo inhibitor study
Table 6: Protein band images of in vivo inhibitor study
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